Activation of the cardiac non-neuronal cholinergic system prevents type-1 diabetes-induced cardiovascular dysfunction by Munasinghe, Pujika Emani
i 
 
Activation of the cardiac non-neuronal 




Pujika Emani Munasinghe 
Supervisors: A/P Rajesh Katare 
&  







A thesis submitted in partial fulfilment of the requirements for the degree of 
Masters in Science in Physiology at the University of Otago, Dunedin, New 
Zealand  
 





The cardiac non-neuronal cholinergic system (cNNCS) is a newly described system where the 
cardiomyocytes possess the ability to synthesise and release acetylcholine (ACh) that acts in an 
auto-/paracrine manner to induce cardioprotective effects. In this study, we determined the 
effects of type-1 diabetes mellitus (T1DM) on the expression of the cNNCS components 
namely choline acetyltransferase (ChAT), choline transporter-1 (CHT-1: rate-limiting step of 
ACh synthesis), vesicular acetylcholine transporter (VAChT), and acetylcholinesterase (AChE) 
which synthesise, release and degrade acetylcholine (ACh) respectively. Secondly, we 
determine the potential therapeutic effect of activation of the cNNCS in preventing T1DM 
induced cardiovascular dysfunction. T1DM was chemically induced by injection of low dose 
streptozotocin (STZ, 50mg/kg, i.p) over five consecutive days in C57Bl6 mice (T1DM; n=6) 
by our collaborator Prof Yoshihiko Kakinuma at Nippon Medical School, Japan. Age-matched 
healthy mice served as controls (ND; n=6). To determine the effects of activation of the cNNCS 
on T1DM, mice with cardiomyocyte-specific overexpression of the ChAT gene in the ventricles 
were injected with STZ to induce T1DM (ChAT-TG-T1DM; n=6). The western blotting 
analysis demonstrated that CHT-1 expression in T1DM mice at 16-weeks after STZ injection 
was significantly decreased. Interestingly, the western blotting analysis in T1DM mice 
compared to ND mice showed marked impairment in the downstream targets of pro-survival 
AKT pathway such as pAkt/Akt (activate mammalian target of rapamycin 1/2 to reduce fibrosis) 
and Bcl-2 (anti-apoptotic protein) at all time points. Further, evaluating apoptosis (determined 
by TUNEL positive nuclei) and fibrosis (determined by Picro-Sirius staining) showed a 
significant increase in apoptotic and fibrotic area at all time points. All these consequently 
resulted in T1DM-induced cardiac dysfunction, as reflected by the manifestation of both 
diastolic (reduced ejection fraction, increased end-diastolic volume) and systolic dysfunction 
(increased end-systolic volume). However, at the same time, western blot analysis in ChAT-
TG-T1DM mice compared to T1DM mice resulted in a significant increase in CHT-1 along 
with an increase in pAkt and Bcl-2 expression. Moreover, apoptosis and fibrosis were 
significantly decreased in ChAT-TG-T1DM mice compared to T1DM mice preventing cardiac 
dysfunction. In conclusion, our results provide the first evidence that the cNNCS is altered in 
the T1DM heart and activation of the cNNCS prevented the alterations, to improve cardiac 
function and reduce apoptosis and fibrosis. Taken together, targeting cNNCS to increase the 
availability of ACh can be a potential therapeutic intervention, which will prevent the 
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All organisms control their physiology through a dynamic mechanism known as homeostasis. 
This enables the maintenance of the most favourable internal environment for the organism and 
ensures that physiological processes are carried out effectively and efficiently. Thus, 
homeostasis acts to buffer any modification back to a set point where these processes can 
function within an ideal range (Retnakaran & Zinman, 2008). When this internal state is 
challenged, responses are initiated (De Ferranti et al., 2014). The responses activated can alter 
the ideal range as part of homeostasis to restore the conditions where the internal environment 
is ideal again. However, in certain conditions such as autoimmune diseases like type 1 diabetes 
mellitus, responses activated due to the changes in the internal environment fail to restore the 
conditions to the ideal range again or to restore homeostasis.  Therefore, firstly type 1 diabetes 
mellitus and consequently changes in homeostasis will be described below. 
 
1.2 Type 1 Diabetes mellitus 
 
Type-1 Diabetes Mellitus (T1DM) is characterised by the absolute deficiency of insulin 
production, as a result of the destruction of insulin-producing β cells in the pancreas via T cell 
immune-mediated pathway (Atkinson et al., 2014). The cause of this destruction is not fully 
understood, and researchers believe that it could be due to genetics or infections (Atkinson et 
al., 2014).  Insulin has two vital functions that relate to overall homeostasis (Porte, 2006). 
Firstly, being the maintenance of sufficient energy stores to allow for growth, reproduction and 
development, also known as energy metabolism (Porte, 2006). Secondly, regulating plasma 
glucose, also known as glucose metabolism (Atkinson et al., 2014).   Dysregulation of energy 
and glucose metabolism due to the lack of insulin offsets homeostasis; therefore, T1DM  has 
become a worldwide epidemic. Therefore, it is appropriate to give a background on the 






T1DM accounted for 5-10 % of the 387 million people reported living with diabetes worldwide 
in 2014 (Maahs et al., 2010; Atkinson et al., 2014). In New Zealand, between 1990 and 2009 
in 0-14-year-olds, the incidence of T1DM increased from 10.9 per 100,000 to 22.5 per 100,000 
(Derraik et al., 2012). Interestingly, the prevalence of T1DM is increasing worldwide across all 
age groups in parallel to increasing access to health care, level of wealth, and comfort (You & 
Henneberg, 2016).  Although the numbers seem to be lower when compared to type-2 diabetes 
mellitus (T2DM), it is important to note that the interplay between an individual’s genes and 
their exposure to a wide range of environmental triggers such as viral infection and bacterial 
toxins which contribute to the heterogeneity of T1DM is inevitable (Maahs et al., 2010; 
Atkinson et al., 2014). In contrast, the cause of T2DM are mostly lifestyle choices, which can 
be regulated.  
 
It should be noted that T1DM related mortality rate is still higher than in age-matched controls 
without diabetes (Schnell et al., 2013). Cardiovascular disease (CVD) takes precedence among 
the T1DM related mortality rate, and there is a significant increase in CVD mortality reported 
in T1DM with increasing blood sugar levels (Schnell et al., 2013). A meta-analysis conducted 
by Huxley et al. estimated the overall mortality rate linked to CVD in individuals with T1DM 
to be 5.7 for men and 11.3 for women (Huxley et al., 2015). Recent long-term follow-up of 
patients registered in the Swedish National Diabetes Register found that improved management 
of established risk factors had no effect on hospitalisations for CVD in patients with T1DM 
(Lind et al., 2012). In contrast, T2DM patients had a more significant event-rate reduction than 
their matched controls (Lind et al., 2012), suggesting that pathophysiology contributing to CVD 
risks are not addressed in T1DM patients, and current clinical care is lacking for patients with 
T1DM. Since CVD contributes most to the mortality rate of T1DM, the current thesis will be 
discussing changes in homeostasis and consequent complications observed in T1DM through 




1.4 Energy Metabolism in the T1DM  heart 
 
Energy metabolism is the process of generating energy or adenosine triphosphate (ATP) from 
nutrients, and metabolism consists of series of interconnected pathways that can function in the 
presence of oxygen (aerobic conditions) or absence of oxygen (anaerobic conditions). The heart 
is an aerobic organ which depends on the oxidation of substrates such as free fatty acids (FFAs), 
lactate and glucose to generate ATP (Pulinilkunnil et al., 2013). Predominantly the heart 
metabolises FFAs as its main energy substrate contributing to 70 % of ATP synthesis, where 
glucose and lactate contribute to the remaining ATP production (Pulinilkunnil et al., 2013). A 
healthy heart is flexible and possesses the ability to adapt to the changes in the environment by 
switching to the available substrate to generate the needed ATP for the functioning of the heart 
and to maintain homeostasis. For instance, FFAs utilisation is predominant in the fasted-state; 
glucose utilisation is predominant in fed-state, and lactate utilisation is predominant during 
exercise under normal physiological conditions (Gertz et al., 1988; Schönekess, 1997). 
 
In contrast, in T1DM, the lack of insulin causes the suppression of hormone-sensitive lipase in 
adipose tissue and increases the secretion of very-low-density lipoprotein (VLDL) from the 
liver, thus increasing the level of circulating FFAs (Chong et al., 2017). Consequently, 
elevating the FFA’s availability changes the environment in such a way which fails to restore 
homeostasis. The T1DM heart is inflexible and cannot adapt to the changes; thus, it promotes 
cardiac FFAs uptake, storage, and oxidation (Pulinilkunnil et al., 2013). This increased in 
plasma FFAs was associated with decreased basal cardiac energy status in diabetic patients 
(Scheuermann-Freestone et al., 2003). Furthermore, excessive FFAs utilisation also decreases 
mitochondrial oxygen capacity, thereby reducing the ATP production in the diabetic heart (How 
et al., 2006). It is plausible that the persistent lack of insulin in T1DM causes changes in energy 
metabolism, offsetting homeostasis, thereby affecting the heart in working effectively and 
efficiently.  
 
1.5 Glucose Metabolism in the T1DM heart 
 
Glucose metabolism is the process of balancing the rate of glucose entering the circulation and 
the removal of glucose from the circulation (Shao & Tian, 2015). Glucose mainly enters the 
circulation through the food ingested, and glucose is removed via glucose transporter- 4 
(GLUT4) from the circulation in the heart (Shao & Tian, 2015). Under normal conditions 
5 
 
following insulin stimulation, activation of the signalling cascade leads to translocation of 
GLUT4 to the plasma membrane in order to take up the circulating glucose into the myocardium 
to generate ATP (Shao & Tian, 2015). Consequently, it provides energy to the heart and 
removes glucose from the circulation, thus maintaining homeostasis. 
 
However, in T1DM, insulin deficiency leads to a decrease in GLUT4 expression in the heart, 
resulting in inadequate cardiac glucose transport and oxidation, thereby further reducing the 
ATP production (Shao & Tian, 2015). Decreased GLUT4 expression also means glucose 
removal rate from the circulation reduced, leading to high plasma glucose concentration, also 
known as hyperglycemia (Chong et al., 2017). Persistent hyperglycemia results in 
dysregulation of glucose metabolism, thereby offsetting homeostasis (Retnakaran & Zinman, 
2008). As homeostasis is not maintained in T1DM, prolonged exposure to metabolic 
derangements contributes to both macrovascular (damage to larger blood vessels) and 
microvascular complications (damage to small blood vessels) (Retnakaran & Zinman, 2008; 
De Ferranti et al., 2014). Microvascular damage affects specifically the retina, kidneys, both 
the peripheral and autonomic nervous system, while the heart, brain, and lower limbs are 
affected by both macro- and microvascular disorders (Schnell et al., 2013). These complications 
reduce blood flow to and from the heart, thereby reducing the availability of oxygen in the 
cardiovascular system (Retnakaran & Zinman, 2008).  
 
In this instance, the combinational effect of decreased oxygen availability, excessive FFAs 
accumulation (Scheuermann-Freestone et al., 2003), reduced mitochondrial oxygen capacity 
(How et al., 2006), defective glucose metabolism (Shao & Tian, 2015), impaired ATP 
production and contractile function in the T1DM heart, contributes to cardiac dysfunction and 
CVD (Orchard et al., 2006). CVD caused by a consequence of the pathophysiology of TIDM 
induced microvascular and macrovascular complications (Retnakaran & Zinman, 2008; De 






1.6.1 Oxidative stress and endothelial 
dysfunction 
 
Oxidative stress is an imbalance between reactive oxygen species (free radicals) and 
antioxidants in the body (Paneni et al., 2013). Reactive oxygen species (ROS) are oxygen-
containing molecules with an uneven number of electrons which makes them more susceptible 
to reacting with other molecules, and these reactions can be beneficial or harmful (Paneni et 
al., 2013). Antioxidants are molecules that can donate an electron to a ROS to stabilise and turn 
it to less reactive molecules (Paneni et al., 2013). Hyperglycemia in T1DM triggers the 
activation of protein kinase C (PKC) to produce ROS in endothelial cells (Paneni et al., 2013). 
Accumulation of  ROS also triggers upregulation of pro-inflammatory genes such as monocyte 
chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), and 
intracellular cell adhesion molecule-1 (ICAM-1) through the activation of the nuclear factor 
kappa B (NF-κB) signalling pathway (Paneni et al., 2013), which increases monocyte adhesion 
and secretion of inflammatory cytokines. This leads to vascular inflammation and the 
proliferation of smooth muscle cells, which thickens the basement membrane of the endothelial 
cell lining in the blood vessels (Paneni et al., 2013). 
 
Endothelial dysfunction is the inability of the blood vessels to maintain vascular tone, to 
regulate inflammation, and to act as a barrier to potentially toxic material, ultimately resulting 
in a reduction in blood flow (Paneni et al., 2013).  Matching oxygen delivery with increased 
oxygen demand to maintain cardiac metabolism in the myocardium is achieved by the coronary 
arterial circulation. The coronary arterial circulation consists of conductance and resistance 
vessels, which are lined by a layer of cells known as the endothelium comprised of a single 
layer of endothelial cells. Therefore, endothelial dysfunction in coronary arteries can lead to 
subsequent myocardial ischaemia and CVD.  As described above, hyperglycemia in T1DM 
triggers the activation of protein kinase C (PKC), and along with ROS production, it also 
dysregulates endothelial nitric oxide synthase (eNOS) which is involved in the production of 
nitric oxide to maintain vascular tone in the cardiovascular system (Paneni et al., 2013). 
Increased ROS further inactivates the vasodilator nitric oxide (NO). PKC also enhances eNOS 
uncoupling, leading to further accumulation of ROS (Paneni et al., 2013). Together with 
glucose-induced PKC activation and the lack of vasodilator NO, there is an increased synthesis 
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of endothelin-1 (ET-1), which favours vasoconstriction and platelet aggregation. All these 
collectively lead to a further increase in both oxidative stress and endothelial dysfunction. 
 
1.6.2 Cardiomyocyte cell death 
 
Cardiomyocyte cell death is a highly organised process where the cells lose their ability to carry 
out their function (Chowdhry et al., 2007). Cardiomyocytes can undergo apoptosis, a self-
inflicted death programme encoded in the genetic material of the cell or necrosis, an alternative 
mechanism of cell death of extreme cellular insults or failure of homeostasis (Chowdhry et al., 
2007). Both apoptosis and necrosis are the hallmarks of T1DM linked CVD, and this has been 
demonstrated in both T1DM human and mice cardiac tissue (Chowdhry et al., 2007; 
Williamson et al., 2010). The molecular mechanisms responsible for apoptotic cell death and 
necrosis in the diabetic heart are well established (Lee & Pervaiz, 2007). Hyperglycemia-
induced ROS production in the heart depolarises the membrane potential in the mitochondrial 
membrane in the cardiomyocyte (Lee & Pervaiz, 2007). This depolarisation increases 
mitochondrial permeability transition (MPT) and opens the mitochondrial permeability 
transition pore (PTP), which allows the release of pro-apoptotic/necrotic factor cytochrome C 
(Halestrap et al., 1998). Cytochrome C then activates caspase-3, inducing apoptosis, as outlined 
in figure 1.1 (Cai et al., 2002). In addition, cytochrome C further facilitates necrosis (discussed 
below). Besides the cytochrome c-mediated pathway, apoptosis can also be initiated by binding 
of ligands such as tumour necrosis factor -α (TNF-α) to its receptors, which activates caspase-
8 and subsequently caspase-3, leading through to the extra-mitochondrial mediated pathway 
(Figure 1.1) (Cai et al., 2002).  
 
Furthermore, the opening of the mitochondrial PTP can interfere with myocardial calcium 
(Ca2+) uptake resulting in increased intracellular Ca2+ concentration that also facilitated 
necrosis (Cai et al., 2002). This increased intracellular Ca2+ concentration leads to the 
development of excessive contractile force due to Ca2+ overload. This phenomenon is called 
‘hypercontracture’ and is characterised by extreme cell shortening, eventually leading to 
necrosis, another cardiomyocyte cell death mechanism, outlined in figure 1.1 (Ruiz-Meana et 
al., 1999).  Cytochrome C release from the opening of PTP decreases the activity of the electron 
transport chain, leading to the depletion of ATP, which in turn also activates necrosis (Figure 
1.1) (Halestrap et al., 1998; Cai et al., 2002). Apoptosis and necrosis are two separate molecular 
mechanisms which collectively lead to T1DM-induced cell death, one of the underlying 





Figure 1.1: Schematic diagram representing the mechanism of cell death in the 
diabetic heart. 
Reactive oxygen species (ROS) alter the membrane potential increasing 
mitochondrial permeability transition (MPT), thus causing the opening of the 
mitochondrial permeability transition pore (PTP). Consequently, it leads to the 
release of pro-apoptotic factors such as cytochrome C. Cytochrome C activates 
caspase-3 via caspase-9 and along with the binding of ligands such as Tumour 
Necrosis Factor-α (TNF-α) to its respective receptors further activates caspase-3 
through caspase-8 which collectively leads to apoptosis. Cytochrome C also 
causes the depletion of adenosine triphosphate (ATP) through decreased electron 
transport chain activity, which induces necrosis. In addition, the opening of PTP 
will also increase intracellular uptake of Ca2+ leading to the phenomenon 





1.6.3 Cardiac Fibrosis  
 
Cardiac fibrosis is the accumulation of extracellular matrix components, leading to disrupted 
tissue function in the heart.  T1DM-associated fibrosis is the accumulation of type I and III 
collagen, which involves both the left and right ventricle (Russo & Frangogiannis, 2016) 
(Rawal et al., 2017; De Blasio et al., 2020). A study examining biopsies from T1DM patients 
with heart failure in the absence of coronary diseases revealed increased collagen levels only 
in patients with reduced ejection fraction (van Heerebeek et al., 2008). T1DM patients with 
aortic stenosis possessed increased myocardial stiffness and myocardial collagen content (De 
Blasio et al., 2020). 
 
Following hyperglycaemic stimuli, circulating and myocardial profibrotic growth factors and 
cytokines are increased, triggering a fibrotic response (Kong et al., 2014). Profibrotic growth 
factors and cytokines bind to their receptors, triggering the activation of signalling pathway and 
transcriptional factors including Smad and NF-κB (Kong et al., 2014; Russo & Frangogiannis, 
2016), which consequently transforms cardiac fibroblasts into myofibroblasts (Figure 1.2). 
Myofibroblasts express α-smooth muscle actin, a highly contractile protein which produces 
several matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) 
to regulate homeostasis of the extracellular matrix (Kong et al., 2014; Russo & Frangogiannis, 
2016). As shown in figure 1.2, these profibrotic transcriptional factors regulate the synthesis 
and secretion of profibrotic growth factors and cytokines in cardiac fibroblasts. Further, the 
growth factors and cytokines secreted by cardiac fibroblasts, cardiomyocytes, endothelial cells 
and inflammatory cells, can also act on cardiac fibroblasts or cardiomyocytes in a positive 
feedback manner, eventually amplifying the fibrotic response (Kong et al., 2014). In addition, 
hyperglycemia-induced generation of ROS, advanced glycation end-products (AGEs) and 
neurohormonal activation also directly activate cardiac fibroblasts, inducing a proliferative 
response and a matrix-synthetic phenotype (Russo & Frangogiannis, 2016). Overall, cardiac 





Figure 1.2: Schematic diagram representing the mechanism of fibrosis in the 
diabetic heart.   
Reactive oxygen species (ROS), advanced glycation end-products (AGEs), circulating 
myocardial profibrotic growth factors and cytokines are increased, triggering a fibrotic 
response following a hyperglycemic stimulus. Profibrotic growth factors and cytokines 
bind to their receptors, triggering the activation of the signalling pathway and 
transcriptional factors including Smad and NF-κB, which consequently transforms 
cardiac fibroblasts into myofibroblasts. Myofibroblasts express α-smooth muscle actin, 
a highly contractile protein which produces several matrix metalloproteinases (MMPs) 
and tissue inhibitor of metalloproteinases (TIMPs) to regulate homeostasis of the 
extracellular matrix. Profibrotic growth factors and cytokines secreted by cardiac 
fibroblasts, endothelial cells and inflammatory cells, also act on cardiac fibroblasts in a 
positive feedback manner, eventually amplifying the fibrotic response. Original 
diagram by Emani Munasinghe  
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1.6.4  Plaque Formation 
 
Plaque formation is a lipoprotein-driven process which is defined by the deposition of 
cholesterol, calcium and waste products (or plaque) at specific sites of the arterial tree through 
intimal inflammation, necrosis, fibrosis, and calcification leading to a condition called 
atherosclerosis (Schnell et al., 2013). As a consequence of persistent changes to homeostasis 
triggered by hyperglycemia, this process is significantly accelerated (Schnell et al., 2013).  This 
section will discuss the known mechanisms leading to atherosclerosis in T1DM. 
 
 In T1DM, lack of insulin activates intracellular hormone-sensitive lipase, which increases the 
release of  FFA from triglycerides stored in the adipose tissue (Retnakaran & Zinman, 2008; 
Schofield et al., 2016; Schofield et al., 2019). Increased levels of circulating FFA causes 
increased production of hepatic triglyceride resulting in increased secretion of apolipoprotein B 
(ApoB). Furthermore, the inhibitory effect of insulin on hepatic apoB production and 
triglyceride secretion from very-low-density lipoprotein (VLDL) is lost in the T1DM state and 
therefore, the VLDL secreted is larger and richer in triglycerides (Retnakaran & Zinman, 2008; 
Schofield et al., 2016; Schofield et al., 2019). Reduced VLDL catabolism further contributes 
to T1DM linked hypertriglyceridemia.  
 
Lipoprotein lipase located on vascular endothelium determines the removal rate of triglycerides 
from the circulation. However, in insulin deficiency state of T1DM  intracellular hormone-
sensitive lipase may be downregulated thus failing to remove the circulating triglycerides 
leading to hypertriglyceridemia (Retnakaran & Zinman, 2008; Schofield et al., 2016; Schofield 
et al., 2019). In addition, the cholesteryl ester transfer protein transfers cholesteryl ester from 
other lipoproteins into the enlarged circulating pool of triglyceride-rich lipoproteins, and this 
rate of transfer is increased in T1DM (Retnakaran & Zinman, 2008; Schofield et al., 2016; 
Schofield et al., 2019). Correspondingly, transfer of triglyceride in the opposite direction is 
such that cholesteryl ester-depleted high-density lipoprotein (HDL) and low-density lipoprotein 
(LDL) become triglyceride-rich (Retnakaran & Zinman, 2008; Schofield et al., 2016; Schofield 
et al., 2019). Subsequent removal of triglyceride by hepatic lipase results in smaller, denser 
HDL and LDL particles. Collectively, all these contribute to dyslipidemia in T1DM. 
 
Dyslipidemia induces local inflammation in the vascular wall, which leads to plaque formation 
in T1DM related CVD. The process of formation of plaque consists of several steps, which are 
as follows. Firstly, vascular endothelial cells injured by oxidative stress express adhesion 
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molecules and release cytokines and chemokines (Retnakaran & Zinman, 2008; Schofield et 
al., 2016; Schofield et al., 2019) (Figure 1.3). These chemokines then attract monocytes from 
the circulation to the injured area, which attach to the endothelium through interaction with 
adhesion molecules (Retnakaran & Zinman, 2008; Schofield et al., 2016; Schofield et al., 
2019). As a result, monocytes penetrate the subendothelial space, differentiate, and mature into 
macrophages which also release cytokines. Since LDL cholesterol levels are high in T1DM as 
a result of dyslipidemia, LDL cholesterol infiltrates the subendothelial space and is retained in 
the intima, where it undergoes oxidation (Retnakaran & Zinman, 2008; Schofield et al., 2016; 
Schofield et al., 2019). Accumulated oxidised LDL cholesterol is then taken up by 
macrophages, leading to the formation of foam cells and atherogenesis (Figure 1.3).  Moreover, 
oxidised lipids trigger the secretion of various growth factors by the endothelium, which causes 
the vascular smooth muscle cells of the media to transform and migrate into the intima, where 
they proliferate and actively produce extracellular matrix (Retnakaran & Zinman, 2008; 
Schofield et al., 2016; Schofield et al., 2019). Lastly, the transformed vascular smooth muscle 
cells also take up oxidised LDL cholesterol and transform to form cells that further contribute 
to plaque formation or atherosclerosis.  
 
Progression of plaque formation is further accelerated by advanced glycation end products 
(AGEs) (Retnakaran & Zinman, 2008; Schofield et al., 2016; Schofield et al., 2019). AGEs are 
formed during the early stage of protein glycation products undergoing complex reactions, such 
as oxidation, dehydration, and condensation (Retnakaran & Zinman, 2008; Schofield et al., 
2016; Schofield et al., 2019). Protein glycation is triggered by hyperglycemia, oxidative stress, 
and/or inflammatory reactions. AGEs are involved in each step of plaque formation by 
accelerating the further insult (Retnakaran & Zinman, 2008; Schofield et al., 2016; Schofield 
et al., 2019). The plaques found in T1DM were soft, fibrous with blockages of symmetric 
narrowing, namely concentric lesions, compared to non-diabetic patients (Schofield et al., 
2019). Two studies (Colhoun et al., 2000; Dabelea et al., 2003) compared non-diabetic patients 
with T1DM and observed that there was excess coronary artery calcification (CAC) in T1DM, 
further supporting the observation of accelerated plaque formation in the coronary arteries 
found in T1DM. Notably, the Pittsburgh Epidemiology of Diabetes Complications study 
observed CAC reflecting plaque formation and the strong correlation between CAC with CVD 







Figure 1.3: Plaque formation  
Low-density lipoprotein (LDL) cholesterol enters dysfunctional endothelium which is 
damaged by type 1 diabetes mellitus, which is reflected by decreased nitric oxide (NO) 
production and is oxidised by macrophage and smooth muscle cells. Release of growth 
factors and cytokines, and upregulation of adhesion molecules, attract further 
monocytes. Foam cells accumulate and smooth muscle cells proliferate, which results 
in the growth of the plaque. Inflammatory cell infiltration, smooth muscle cell death 
through apoptosis, and matrix degradation through proteolysis (by matrix 
metalloproteinases-MMPs) generate a vulnerable plaque with a thin fibrous cap and 
lipid-rich necrotic core. Plaque rupture can cause thrombosis, which might be sufficient 
to cause vessels occlusion. Original diagram by Emani Munasinghe  
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1.6.5  Neuropathy in T1DM 
 
Neuropathy is damage or dysfunction of one or more nerves that typically results in numbness, 
tingling, muscle weakness and pain in the affected area (Fowler, 2008). Diabetes can affect 
both the autonomic and peripheral nervous system (Fowler, 2008). Hyperglycemia activates 
polyol pathway converting intracellular glucose to sorbitol and fructose, consequently leading 
to the depletion of other organic osmolytes such as myoinositol (Louraki et al., 2012). Depletion 
of myoinositol impairs the activation of Na+/K+‐ATPase, leading to nerve conduction defects 
(Sima & Kamiya, 2006). In addition, the hyperglycemia-induced formation of AGEs modifies 
myelin which is endocytosed by the macrophages — eventually leading to the myelin loss seen 
in diabetes-related neuropathy (Louraki et al., 2012).  AGEs also modify tubulin, neurofilament 
and actin, leading to axonal atrophy, degeneration and impaired axonal transport (Louraki et 
al., 2012). 
 
T1DM patients lose β-cells as a consequence of  T cell-mediated immunity which leads to the 
production of antibodies against healthy β-cells, known as an autoimmune response.  Therefore 
autoimmunity plays a vital role in T1DM. Consequently, children with T1DM have been found 
to have elevated serum levels of anti-elastin antibodies resulting in elastin degradation, which 
also correlates with neuropathy (Nicoloff et al., 2006). Abnormalities in nerve growth factors 
and the possible direct neurotrophic effects of insulin and insulin-related growth factors may 
further contribute to neuropathy (Louraki et al., 2012). All these collectively lead to functional 
and structural abnormalities in the nervous system contributing to the development of CVD.   
 
1.7 Innervation of the heart 
 
Both sympathetic and parasympathetic nerves innervate the cardiac tissue. These nerves are 
involved in the communication between the central nervous system and the heart (Olshansky 
et al., 2008; San Mauro et al., 2009). Under normal physiological circumstances, there is a 
balance in the sympathetic and parasympathetic input to the heart. However, excessive 
dysregulation of either the sympathetic or parasympathetic system can have fatal consequences 
(Olshansky et al., 2008).  
 
The predominant neurotransmitter of the sympathetic nervous system is norepinephrine (NE) 
(Triposkiadis et al., 2009). Activation of the sympathetic nervous system releases the 
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neurotransmitter NE which increases the strength of cardiac muscular contraction (inotropy) 
and increases the electrical conductivity in the sinoatrial node leading to an increase in heart 
rate (chronotropy) (Triposkiadis et al., 2009). The parasympathetic nervous system achieves its 
control of the heart through the vagus nerve, which originates from the brainstem (San Mauro 
et al., 2009). While acetylcholine (ACh) modulates neurotransmission in ganglia through 
nicotinic receptors, in the post-ganglionic parasympathetic nerves, ACh affects cardiac 
muscarinic receptors (Olshansky et al., 2008). In contrast to the activated sympathetic nervous 
system, activation of the parasympathetic nervous system lead to a reduction in electrical 
conductivity resulting in a lower heart rate and decreased strength of cardiac muscular 
contraction (Triposkiadis et al., 2009).  
 
Both sympathetic and parasympathetic nervous systems innervate the base of the heart to a 
more considerable extent compared to the apex, and the atria are more abundant in neurons 
from both sympathetic and parasympathetic systems compared to the ventricles (Kent et al., 
1974). Since the distribution of sympathetic and parasympathetic nerves within the heart is not 
uniform, the cardiac nervous system has adapted to amalgamate information from sources such 
as the sympathetic and parasympathetic nervous systems, sensory neurons, local interneurons 
and local paracrine signals (Hardwick et al., 2009). Therefore, it is essential to understand 
further how the above mentioned nervous system regulates heart activity since this system 
seems to be involved not only in the heart physiology but also in cardiac pathologies such as  
ventricular (Armour, 2008) and atrial arrhythmias (Armour et al., 2005). 
 
1.8 The neuronal cholinergic system in the 
heart 
 
Neuronal Cholinergic system is composed of organised cells that use acetylcholine (ACh) as a 
neurotransmitter in the transduction of nerve impulses. Nerve cells that consist and release ACh 
during the propagation of a nerve impulse, thus the name neuronal cholinergic system 
(Kawashima & Fujii, 2008). It plays a vital role in the organism as a critical neurotransmitter 
in cholinergic synapses (Figure 1.4 A) in the central and the peripheral nervous system 
(Kakinuma et al., 2005). In the neuronal pre-synaptic terminal, ACh is synthesised from Acetyl-
Co A and free choline via choline acetyltransferase (ChAT) (Figure 1.4 A) (Kakinuma et al., 
2005). In the peripheral nervous system, carnitine acetyltransferase may also participate in ACh 
synthesis (Tuček, 1982). Acetyl-Co A is a product of pyruvate metabolism and can be found in 
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the majority of cells. Pyruvate is the output of glucose metabolism (glycolysis) where one 
molecule of glucose breaks down into two molecules of pyruvate (Gray et al., 2014). A decrease 
in glucose metabolism in conditions such as T1DM will lead to a decrease in pyruvate, thus 
resulting in a decreased amount of Acetyl Co-A, and consequently reduces cholinergic function 
(Jankowska‐Kulawy et al., 2010). 
 
The second substance necessary for ACh synthesis is free choline, and in the presynaptic nerve, 
re-uptake of choline from the synaptic cleft occurs via the Na+-dependent, high-affinity choline 
transporter CHT-1, following the hydrolysis of ACh by the enzyme acetylcholinesterase 
(AChE) (Rocha-Resende et al., 2012; Saw et al., 2018b). Other sources of choline are 
phospholipids, which serve as a storage pool for ACh synthesis (Prado et al., 2002). High-
affinity choline uptake via CHT1 is the rate-limiting step in ACh synthesis (Okuda, 2016). 
Recent studies indicate that CHT1 is also found intracellularly in vesicles and can migrate 
between the vesicles and the membrane (Ferguson & Blakely, 2004). 
 
Synthesised ACh is taken up by vesicular ACh transporter (VAChT) which is also involved in 
the storage and release of ACh upon stimulation (Rocha-Resende et al., 2012; Saw et al., 
2018b).  This protein is localised on the vesicular membrane and mediates the exchange of ACh 
for two protons. Cholinergic nerve synapse release of ACh from vesicles requires the presence 
of extracellular calcium ions (Olshansky et al., 2008). Subsequently, vesicles move towards the 
membrane and ACh is released into the synaptic cleft by exocytosis, where it stimulates type 2 
muscarinic ACh receptor (M2AChR) found on the surface of cardiac cells. M2AChR is an 
inhibitory G-protein-coupled receptor found abundantly in the heart (Rocha-Resende et al., 
2012; Gavioli et al., 2014; Saw et al., 2018b). However, expression of M2AChR is relatively 
low in the ventricles compared to the atria, sinoatrial node and atrioventricular node (Kent et 
al., 1974). Upon stimulation, M2AChR reduces the force of cardiac muscle contractility via 
shortening the duration and conduction velocity of the action potential (Saw et al., 2018b), thus 
reducing the overall heart rate. Collectively, ChAT, CHT1, AChE, VAChT and M2AChR 
proteins are considered as cholinergic markers and used as key proteins to study the functions 
of neuronal cholinergic system (Figure 1.4 A). 
 
Hyperglycemic conditions leading to neuropathy result in decreased neuronal cholinergic 
activity (Fowler, 2008). This decrease in cholinergic activity correlates with many 
cardiovascular conditions such as myocardial infarction, hypertension, arrhythmia and heart 
failure (Fowler, 2008). Jungen and co-workers (Jungen et al., 2017) examined the shortening 
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of ventricular refractory periods, increase in ventricular arrhythmia and decrease in ventricular 
cAMP levels in murine hearts following the mechanical disruption or pharmacological 
blockade of cholinergic innervation. Another study identified significantly lower cholinergic 
activity in 21 patients during the first 24 hours of acute myocardial infarction (McAreavey et 
al., 1989).  
 
Interestingly, the acetylcholinesterase inhibitor- Donepezil, used in the treatment of Alzheimer 
disease, demonstrated an increase in ACh availability and a cardioprotective effect in animal 
models (Okazaki et al., 2010). Similarly, vagal nerve stimulation mediated increase in ACh, 
modulated the adrenergic drive and the cardiac redox status, thereby suppressing free radical 
generation in the failing murine heart(Tsutsumi et al., 2007). Another study showed that 
increasing the level of ACh protected the heart from ischemia-reperfusion injury and improved 
survival in conditions of chronic heart failure, such as myocardial infarction (Kakinuma et al., 
2005). In support of this, DOnepezil Cardiac TEst Registry (DOCTER) trial demonstrated a 
significant reduction in plasma brain natriuretic peptide (BNP) levels in patients with 
subclinical chronic heart failure. 
 
All these studies suggest that ACh exerts cardioprotective effects. However, due to inadequate 
neuronal cholinergic innervation in the ventricles, it remains an enigma to understand the effect 
of ACh in ventricles (Kent et al., 1974). In the last decades, studies to investigate the ability to 
synthesise and utilise ACh in non-neuronal cells including cardiomyocytes have sparked 

















Figure 1.4: Cholinergic system 
A) Schematic diagram summarising the components of the neuronal cholinergic system 
in the heart. B)  Schematic diagram summarising the components of the Non-Neuronal 
Cholinergic System in the heart. Acetylcholine (ACh), choline acetyltransferase 
(ChAT), Vesicular ACh transporter (VAChT)  acetylcholinesterase (AChE), choline 
transporter (CHT1), nicotinic ACh receptor (nAChR), and type 2 muscarinic ACh 





1.9 Non-neuronal cholinergic system in the 
heart  
 
As described above in the neuronal cholinergic system, cardiomyocytes also possess an intrinsic 
cholinergic system to synthesise and release ACh for signal transduction (Saw et al., 2018a). 
Importantly, this occurs irrespective of neuronal innervation or influence, thus the name non-
neuronal cholinergic system (NNCS), and since it is demonstrated within cardiomyocyte, it is 
known as cardiac NNCS (cNNCS)(Rocha-Resende et al., 2012). Studies have demonstrated 
that cNNCS comprises of similar proteins that are associated with the neuronal cholinergic 
system, which also includes ChAT, VAChT, CHT1 and M2AChR (Figure 1.4 B) (Kakinuma et 
al., 2009). In support of this, several studies have demonstrated the expression of cholinergic 
markers ChAT, CHT1, VAChT, and AChE in isolated primary mouse and rat cardiomyocytes, 
where contamination from neuronal cholinergic neurons was eliminated (Kakinuma et al., 
2009; Rana et al., 2010; Rocha-Resende et al., 2012).  
 
Moreover, in the presence of AChE inhibitors such as donepezil, physostigmine, and 
pyridostigmine, ACh derived from cardiomyocytes was detected both intracellularly and 
extracellularly (Kakinuma et al., 2009; Rana et al., 2010; Rocha-Resende et al., 2012).  Rocha-
Resende and co-workers treated mouse cardiomyocytes with hemicholinium-3, a CHT1 
(choline uptake via CHT1 is the rate-limiting step in ACh synthesis) inhibitor to inactivate 
cNNCS, thereby identifying the presence of CHT1 in cardiomyocytes  (Okuda, 2016).   
 
Furthermore, cardiac-specific VAChT and ChAT knockout mice had reduced heart rate 
recovery when subjected to acute low-intensity treadmill exercise compared to the age-matched 
wildtype (Roy et al., 2013), indicating diminished neuronal cholinergic tone as a consequence 
of the impaired ability of cNNCS either to produce or release ACh. An in-vitro study using HL-
1 cardiomyocytes reported an augmented ROS generation and apoptosis in response to 
adrenergic agonist norepinephrine after knocking out ChAT gene (Kakinuma et al., 2012), 
suggesting that cardiomyocytes are vulnerable to sympathetic toxicity in the absence of the 
cNNCS.  
 
These findings cement the fact that cardiomyocytes possess the ability to synthesise, secrete, 
utilise and degrade ACh intrinsically. Therefore,  it is possible to speculate that activation of 
cNNCS is via the neuronal cholinergic system, and ACh released by the cNNCS is vital for 
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cardiovascular function (Roy et al., 2013). Kakinuma and co-workers created a transgenic 
mouse model with cardiac-specific overexpression of the ChAT gene (ChAT-TG) and 
demonstrated increased ACh secretion specifically by the ventricular cardiomyocytes 
(Kakinuma et al., 2013). These ChAT-TG exhibited similar heart rate and blood pressure as the 
wild-type mice under non-stressful condition. Therefore, it is logical to hypothesise that non-
neuronal ACh released from the cardiomyocytes contributes to maintain and intensify neuronal 
cholinergic effect through autocrine and paracrine regulatory loops as cholinergic neurons 
innervate the ventricular myocardium sparingly (Kent et al., 1974). 
 
This is further supported by a study where isolated rat ventricular cardiomyocytes treated with 
the AChE inhibitor- pyridostigmine demonstrated reduced expression of ChAT, VAChT, and 
M2AChR after seven days, further suggesting that the cardiomyocytes possess the ability to 
maintain non-neuronal ACh homeostasis by fine-tuning the intrinsic cholinergic machinery. 
Notably, cNNCS also plays a role in energy metabolism by negatively regulating mitochondrial 
function (Kakinuma et al., 2009; Kakinuma et al., 2012; Oikawa et al., 2014). This was 
confirmed using different types of cardiomyocytes cell models where inactivation of NNCS by 
either ChAT-knock out in HL-1 cardiomyocytes or hemicholinium-3 (CHT1 inhibitor) 
treatment in H9c2 cells displayed increased oxygen consumption, increased mitochondrial 
activity, and decreased intracellular ATP level (Kakinuma et al., 2009; Kakinuma et al., 2012; 
Oikawa et al., 2014). Conversely, overexpression of the ChAT gene or addition of exogenous 
ACh to the HEK293 cells, activated the NNCS leading to decreased mitochondrial function, 
increased intracellular ATP level and resistance to chronic serum deprivation (Kakinuma et al., 
2009; Oikawa et al., 2014). Furthermore, ChAT-expressing cells demonstrated increased 
protein expression of insulin-like growth factor-1 receptor (IGF-1R) and glucose transporter-1 
(GLUT-1), thereby increasing glucose uptake (Oikawa et al., 2014). In vivo experiments carried 
out in ChAT-TG mice also exhibited an increase in protein expression of GLUT-1 and -4, along 
with increased glucose content in the left ventricle compared to the wild-type mice (Kakinuma 
et al., 2013). This suggests a role of the NNCS in glucose metabolism, a possible approach for 
the treatment of diabetes-induced cardiovascular complications. This, in turn, can reduce 
circulating, and myocardial pro-fibrotic growth factors and cytokines restricting the fibrotic 
response (Kong et al., 2014). 
 
Further, studies demonstrated that activation of cNNCS under pathological conditions could 
prevent the progression of cardiac dysfunction associated with autonomic dysfunction, through 
activation of the pro-survival PI3K/Akt signalling pathway (Figure 1.5) (Kakinuma et al., 
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2013). The PI3K/Akt/HIF1-α pathway is involved in survival, proliferation, microvascular 
permeability, and angiogenesis (Hemmings & Restuccia, 2012). Furthermore, a core 
component of class III phosphatidylinositol-3 kinase (PI3K-III) complex, Bcl-2, anti-apoptotic 
protein plays a vital role in the cross-talk and coupling of the PI3K/Akt pathway to reduce 
apoptosis, thereby reducing oxygen demand in the heart (Munasinghe et al., 2016) (Figure 1.5). 
In addition, the PI3K/Akt/HIF1-α pathway also transcriptionally upregulates vascular 
endothelial growth factor, a major proangiogenic factor which in turn increases the oxygen 
supply to the heart by the formation of new blood vessels (angiogenesis) (Kakinuma et al., 
2013). It is well established that increased apoptosis and decreased angiogenesis ultimately lead 
to cardiac dysfunction in diabetes  (Fowler, 2008). Under physiological conditions formation 
of new blood vessels, angiogenesis will occur to increase blood supply to the heart meeting this 
demand (Hemmings & Restuccia, 2012). However, in diabetic conditions, this pro-survival 
pathway, Akt, is downregulated, which accelerates cardiac dysfunction, due to the reduction of 
angiogenesis and increased cardiomyocyte cell death. As discussed above, activation of the 
cNNCS can lead to the activation of the Akt pathway. Hence, it is safe to assume that any 
modulation of the cNNCS will affect downstream targets such as angiogenesis and cell death, 







Figure 1.5: PI3K/Akt/HIF1-α pathway 
Binding of Acetylcholine (ACh) to the type 2 muscarinic ACh receptor (M2AChR), 
which is a G alpha (Gαi/0) protein-coupled receptor can activate the 
phosphatidylinositol 3-kinase (PI3K) pathways. PI3K, in turn, activates Akt (also 
known as Protein kinase B) promoting the inhibition of ubiquitin-mediated proteasomal 
degradation of Hypoxia-inducible factor 1-alpha (HIF-1α) protein. Ubiquitination (u) 
of HIF-1α leads to the removal of phosphorylated Von Hippel-Lindau tumour 
suppressor (pVHL) from HIF-1α, which in turn translocate into the nucleus. 
Consequently, HIF-1α and Hypoxia-inducible factor 1-beta (HIF-1β) dimerise in the 
nucleus to form a master transcription factor which is eventually translated to proteins 
leading to angiogenesis and glycolysis. Activated Akt also increases anti-apoptotic 
protein b cell lymphoma 2 (Bcl-2) reducing cardiomyocyte cell death (apoptosis) via 
the activation of mammalian target of rapamycin 1& 2 (mTOR-1&-2). Original diagram 




Accumulating evidence provided in this chapter clearly indicates a wide range of functional 
roles for the NNCS in various physiopathological processes (Beckmann & Lips, 2013), 
although the role of the NNCS in the cardiovascular system is still in its infancy requiring 
further investigations. Most importantly, to the best of our knowledge, the role of the cNNCS 
in the T1DM setting is an area where no studies have been conducted so far. As T1DM induced 
macro and micro-vascular complications lead to cardiac dysfunction and the development of 
CVD, it would be alluring to investigate further to unravel the role of the cNNCS in the T1DM 
setting and whether it could be a potential target in treating T1DM associated CVD 
complications. 
 
1.10 Aim and Hypothesis 
 
T1DM is an independent risk factor for CVD, and emerging evidence suggests that activation 
of the cNNCS is beneficial in preclinical models of CVD such as after myocardial infarction 
(Kakinuma et al., 2012). However, the effect of T1DM on changing the components of cNNCS 
at different time points of T1DM duration and the beneficial effects of activation of cNNCS in 
the T1DM setting is unclear. A recent PhD study from Katare laboratory demonstrated the 
dysregulation of the cNNCS in the T2DM setting (Saw et al., 2018a), suggesting that similar 
effects could be observed in T1DM. Therefore, the aim of this study is to determine the 
differential expression of the major components of the cNNCS such as ChAT, VChAT, 
M2AChR, CHT-1, and AChE in T1DM setting using streptozotocin-induced type 1 diabetic 
mice model, and to evaluate the effect of ventricular cardiomyocytes specific overexpression 
of ChAT in these mice. Further, we aim to determine whether the overexpression of ChAT in 
T1DM mice will activate the downstream targets of AKT pathway such as Akt and Bcl-2. I 
hypothesise that the cNNCS is impaired in T1DM and activation of cardiac NNCS 










2.1  Ethics 
 
The Animal Ethics Committee from the University of Otago (AEC number 25/12) and Nippon 
Medical School, Japan, approved the animal studies conducted for this Masters study. The 
cardiac tissues for non-diabetic (ND) samples for the study were collected and provided for this 
study by Dr Shruti Rawal (previous PhD student in Katare Lab). Type 1 diabetes mellitus 
(T1DM) and ChAT Transgenic (TG)-T1DM mice cardiac tissues were collected by our 
collaborator Prof Yoshihiko Kakinuma at Nippon Medical School, Japan.  
 
2.2  The study model 
 
Three groups of animals were used in this study. All three mouse groups had a C57BL6 strain 
background, and only male mice were used. The groups were (i) normal age-matched C57BL6 
mice, (ii) C57BL6 mice who were treated chemically to induce T1DM, and (iii) mice with 
ventricular-specific overexpression of ChAT gene which is also treated chemically to induce 
T1DM. Study groups were used to investigate the expression changes of components of the 
cNNCS (ChAT, VAChT, M2AChR, CHT1, and AChE) in the T1DM setting and to investigate 




2.2.1 T1DM mice (n=6; male) 
 
T1DM was induced in 12-weeks old C57BL6 mice through the injection of streptozotocin 
(STZ; 50 mg/kg body weight i.p. per day for five days) by our collaborator Prof Yoshihiko 
Kakinuma at Nippon Medical School, Japan (Katare et al., 2012). STZ induces T1DM as it is 
cytotoxic to pancreatic β-cells leading to a lack of insulin production (Katare et al., 2012). 
Comber Test® E strips were used to confirm T1DM in these mice by measuring the glucose 
level in the urine before recruiting them to the experimental group. Colour of the strip changes 
upon exposure to urine and the degree of change reflects the glucose concentration. Quantitative 
colourimetric scale provided an indication of the concentration of glucose. Mice showing urine 
glucose levels of 50 mg.dL-1 and above were considered to be diabetic or hyperglycaemic 
(increased glucose levels).  
 
2.2.2 ChAT Transgenic (TG) mice (n=6 for all the 
groups except the ChAT TG-T1DM group 
which had n=5; male) 
 
The ChAT transgenic animal model was developed by our collaborator Prof Yoshihiko 
Kakinuma at Nippon Medical School, Japan. An α-Myosin Heavy chain (α‐MHC) promoter 
region to specifically overexpress murine choline acetyltransferase (ChAT) in the heart was 
used to develop the ChAT‐TG mouse model (Kakinuma et al., 2013). 
Mouse ChAT transgene was subcloned with specific primers and confirmed using polymerase 
chain reaction (PCR) (Kakinuma et al., 2013). Once these animals reached 12-weeks of age, 
they were then made T1DM and confirmed hyperglycaemia as described in section 2.2.1.  
 
2.2.3 Non-Diabetic mice (n=6; mixed gender) 
 
Non-Diabetic (ND) mice were age-matched with T1DM-wildtype and ChAT TG-T1DM mice. 
Left ventricular tissue from these mice was collected by a previous PhD student Dr Shruti 




2.3  Measuring left ventricular function 
 
Left ventricular function was measured using a pressure-volume (PV) catheter as described by 
Oikawa et al. (Oikawa et al., 2016). Measurements taken are shown in table 3.1. Briefly, the 
mice were anaesthetised with 1- 2 % isoflurane at a flow rate of 0.5-1.0 L/min. The incision 
was made into the abdominal cavity to allow the PV catheter to be inserted into the apex of the 
heart via the diaphragm. The catheter was connected to an ADVantage PV system control box 
(Transonic Systems) and a data acquisition system (iWorx System). Hemodynamic parameters 
were measured using LabScribe2 software (iWorx System).  
 
2.4  The experimental design 
 
Our collaborator Prof Yoshihiko Kakinuma (Nippon Medical School, Japan) measured left 
ventricular function using a pressure-volume (PV) catheter as described by Oikawa et al. 
(Oikawa et al., 2016), at 4-weeks following STZ injection. The tissue was immediately 
collected following the measurement, while the mice were still under anaesthesia at each time 
point. This was confirmed by the absence of the limb withdrawal reflex. The chest cavity was 
opened to expose and remove the heart. Atrial appendages were cut off, and the remaining 
ventricle was immediately divided into three equal portions (Figure 2.1). Likewise, this protocol 
was repeated at each 8-, 12-, 16-weeks following STZ injection, where the left ventricular 
function was measured followed by the tissue extraction at each time point. At each time point, 
there were six animals per experimental group and samples collected were then shipped to the 
Katare Lab (University of Otago -Dunedin) for analysis (Figure 2.2). Changes in protein 
expression of cNNCS (ChAT, VAChT, M2AChR, CHT-1 and AChE), survival proteins (pAkt, 
Akt, Bcl-2) between ND, T1DM -wildtype and ChAT TG-T1DM mice were quantified by 
western blot analysis as shown in figure 2.2. Furthermore, fibrosis, apoptosis and cardiac 





Figure 2.1 An overview of ventricular tissue collection and analytic techniques 
performed on mice tissue. 
The ventricular tissues were cut into three parts after removal of the atrial tissues. The 
upper part of the ventricular tissue was harvested and fixed in 4 % paraformaldehyde 
for immunofluorescence analysis. The middle portion was stored at -80̊C for gene 
expression studies after harvesting; however, no gene expression studies were carried 






Figure 2.2 An overview of the experimental setup. 
The body weight and blood glucose level were measured. The left ventricular function 
was examined by inserting the pressure-volume catheter into the left ventricle. Western 
blot was performed to assess the expression changes in the components involved in the 
cNNCS-mediated cell survival signalling. Apoptosis and fibrosis were measured using 




2.5  Western blot analysis  
 
Based on the published literature and recent study from the Katare Lab, to investigate the effect 
of T1DM on cNNCS, it was hypothesised that expression of ChAT, VAChT, M2AChR, CHT-
1 and AChE would be changed in T1DM mice and ND (control). To investigate this, we used 
western blot analyses to determine the relative expression levels of ChAT, VAChT, M2AChR, 
CHT-1 and AChE. Furthermore, studies also demonstrated that activation of cNNCS under 
pathological conditions prevents the progression of cardiac dysfunction, through activation of 
the pro-survival Akt signalling pathway (Kakinuma et al., 2013). To investigate the changes in 
the pro-survival signalling pathways in T1DM-wildtype mice and how to address the activation 
of cNNCS has prevented the cardiac dysfunction, the total protein expression level of 
downstream targets such as pAkt, Akt and Bcl-2 were measured using western blot analysis.  
 
2.5.1 Tissue Homogenisation 
 
For immunoblotting, the left ventricular tissue was suspended in 250 μL of tissue protein 
extraction reagent (T-PER™, 78510, ThermoFisher Scientific) supplemented with 1 % protease 
cocktail inhibitor (P8340, Sigma Aldrich) to prevent protein degradation. A Bullet Blender® 
was used to mechanically homogenise the left ventricular tissue, which uses small metallic 
beads to lyse the cells. The tissue was homogenised at a speed setting of 8 in the Bullet Blender® 
(Model # BBX24, Next Advance) for 4 min followed by incubation for 30 min on ice. 
Following initial incubation, if there were still large pieces of tissue remaining, then it was 
further digested at a maximum speed (setting 12) for 2 min. The homogenised tissue samples 
were then centrifuged for 20 min in 4˚C at 15,000 Relative Centrifugal Force (RCF). The 
supernatant which contained the protein was then removed, aliquoted in 100 μL volumes and 
stored at -80˚C in a freezer.  
 
2.5.2 Quantification of proteins  
 
A standard curve with serial dilutions of protein concentrations was constructed using bovine 
serum albumin (BSA, A7906-500G, Sigma Aldrich) as shown in table 2.1. Aliquots of the left 
ventricular tissue supernatant or lysis buffer were diluted 2-fold with T-PER™ supplemented 
with 1 % protease cocktail inhibitor. Two-fold diluted lysis buffer was used as a blank. 
Standards and diluted protein supernatants were added into white flat-bottom 96-well plates, 5 
μL per well, in duplicates. Next, 250 μL of 1x Bradford Dye Reagent (5000205, BioRad) was 
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added into each well and left to develop for 5 min. Finally, absorbance was read at 595 nm 
using a Varioskan LUX Microplate Reader (ThermoFisher Scientific). Protein concentrations 
were determined after plotting the absorbance against the protein standards. For western blot 
analysis, ventricular tissue proteins were diluted with 6x Laemmli buffer (10 % sodium dodecyl 
sulphate (SDS), 250 mM of 0.5 M Tris, pH 6.8, 50 % glycerol, 0.03 % bromophenol blue and 
10 % β-mercaptoethanol) to a final protein concentration of 1 μg/μL and boiled at 95°C for 5 
min, and then immediately aliquoted into 5-6 tubes of 50 μL each. All these aliquots were then 
stored at -80°C. One tube was thawed each time for western blot experiments to avoid multiple 
freeze-thaw cycles and, thus, potential protein degradation.  
 
Table 2.1 Preparation of BSA standards for Bradford assay. 
Tube # BSA volume 
(μL) 






1 20 2 mg/mL stock 0 2,000 
2 30 2 mg/mL stock 10 1,500 
3 20 2 mg/mL stock 20 1,000 
4 20 Tube 2 20 750 
5 20 Tube 3 20 500 
6 20 Tube 5 20 250 
7 20 Tube 6 20 125 
8 - - 20 0 
An example of the calibration curve and the protein analysis is shown in appendix 1.  
 
2.5.3 Protein separation 
 
Four percent of stacking gel and required resolving gel were cast using the recipe, as shown in 
Table 2.2. After assembling the gels, 1x running buffer (25 mM Tris base, 190 mM glycine and 
0.1 % SDS) was transferred to fill up the gel tank. Equal amounts of protein (10 μg) were loaded 
into each well and subjected to gel electrophoresis. Protein ladder (161-0375, BioRad) was 
added into the first well of each gel. 1x Laemmli buffer was loaded into empty wells if present. 
The proteins were subjected to a constant voltage of 80V for 30 min during the 4 % stacking 
gel, followed by the protein separation at a constant voltage of 150V for 1.5 hours. The purpose 
of the stacking gel is to concentrate the proteins in the band (or sample), so they will migrate 
to the resolving gel at the same time, and resolving gel allows separation of the proteins in the 




Table 2.2: SDS-gel recipe. 




10 %  
Resolving Gel 
12 %  
Resolving Gel 
30 % acrylamide/bis  
(1610156, BioRad) 
1.98 mL 3.75 mL 3.3 mL 6.0 mL 
Tris-HCl buffer 0.5 M pH 6.8  
3.78 mL 
1.5 M pH 8.8 
3.75 mL 
1.5 M pH 8.8 
3.75 mL 
1.5 M pH 8.8 
3.75 mL 
10 % SDS 150 µL 150 µL 150 µL 150 µL 
MiliQ Water 9 mL 7.28 mL 7.73 mL 5.03 mL 
10 % ammonium 
persulfate (A3678, 
Sigma Aldrich) 
75 µL 75 µL 75 µL 75 µL 
TEMED (1610801, 
BioRad) 
15 µL 7.5 µL 7.5 µL 7.5 µL 
Total Volume 15 mL 15 mL 15 mL 15 mL 
 
2.5.4 Transfer of proteins  
 
Polyvinylidene Difluoride (PVDF) (1620264, BioRad) membrane was activated by immersing 
in absolute methanol for 1 min. PVDF membrane, filter papers and sponges were equilibrated 
in ice-cold 1x transfer buffer (48 mM Tris base, 39 mM glycine and 20 % methanol) for 10 
min.  A transfer sandwich was assembled in ice-cold transfer buffer in the order illustrated in 
Figure 2.3. Ice packs were placed in the transfer chambers, and the protein was transferred at a 
constant current of 400 mA for an hour in 1x transfer buffer. After the completion of the 
transfer, the PVDF membrane was removed from the cassette and immediately rinsed with 1x 
TBST buffer (tris-buffered saline with Tween 20 solution: 50 mM Tris base, 150 mM sodium 
chloride and 0.1 % Tween 20). The PVDF membrane was then stained in 0.1 % (w/v) Ponceau 
solution in 5 % (v/v) acetic acid and subsequently scanned using EPSON office scanner. Stained 




Figure 2.3: Schematic diagram for the transfer sandwich used in western 
blotting. 
 
2.5.5 Probing with antibodies 
 
Membranes were blocked with 5 % BSA in TBST for 1 hour to avoid non-specific antibody 
binding. After blocking, membranes were probed with primary antibodies overnight at 4°C and 
then incubated with an appropriate secondary antibody for 2 hours at room temperature. 
Primary and secondary antibodies were prepared in 5 % BSA in TBST. Using the shaker the 
membranes were washed each time after antibody incubation with 1x TBST buffer for four 
times, 5 min each wash. Information regarding the antibodies used and dilution factors are 
shown in Table 2.3. Protein expressions were detected using Clarity Enhanced 
chemiluminescence (ECL) Blotting Substrate (1705061, BioRad) and visualised using Syngene 




Table 2.3 Primary and secondary antibodies for western blot. 










AChE  Rabbit/polyclonal 1:1,000 68 Bioss, BS-2511R 
ChAT Goat/polyclonal 1:1,000 70/74 Chemicon, 
AB144P 
CHT1 Rabbit/polyclonal 1:1,000 70-75 Merck Millipore, 
ABN458 
M2AChR Rabbit/monoclonal 1:1,000 52 Abcam, 
AB109226 
VAChT Rabbit/polyclonal 1:1,000 70 Sigma-Aldrich, 
SAB4200560 
pAkt (ser 473) Rabbit/polyclonal 1:1,000 60 Cell Signaling, 
9271 
Akt Rabbit/polyclonal 1:2,000 60 Cell Signaling, 
9272 
Bcl-2 Rabbit/polyclonal 1:1,000 26 Cell Signaling, 
3498S 
Secondary antibodies 
Anti-goat IgG, HRP 
conjugated 
Mouse 1:3,000 - Santa Cruz, 
SC2354 







Note: the predicted molecular weight of the protein is recommended by the manufacturer 
 
2.5.6 Western blot data analysis 
 
Western blot for each time point with the three study groups was repeated 3-4 times, so each 
animal is tested 3-4 times independently. Protein band density was quantified using ImageJ 
analysis software (https://imagej.nih.gov/ij/). The data were expressed as a ratio between the 
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band size (area) of total bands between 25 kDa and 100 kDa from total protein blot (Ponceau S 
stained)  and the band size (area) of protein of interest (Rain et al., 2014).  
 
2.5.7 Validation of western blot analysis 
 
As described above, to investigate the expression of cNNCS components in T1DM mice and 
ND (control), and how to assess the activation of the cNNCS has prevented the cardiac 
dysfunction through pro-survival protein targets such as pAkt, Akt, and Bcl-2 were measured 
using western blot analysis. Therefore, to ensure the accuracy of the results gathered from the 
western blot analysis stated above, experiments in appendix 2-5 were carried out. It was 
confirmed that the quantification of proteins, loading of proteins, and transfer of proteins were 
accurate, consistent and uniform respectively. It was also identified that there is a variability of 
samples within the same animal group.  
 
Table 2.4 Labelling of graphs, western blot and diagrams. 
Label Age  Duration of T1DM 
4W 16-weeks 4-weeks 
8W 20-weeks 8-weeks 
12W 24-weeks 12-weeks 
16W 28-weeks 16-weeks 
 
 
2.6  Immunostaining 
 
Immunostaining is an antibody-based method for the detection of a specific protein in a tissue 
sample to understand the localised expression of the proteins in the tissue 
. 
2.6.1 Cryosection of heart tissue 
 
The ventricular tissue collected for apoptosis and fibrosis measurement (Figure 2.1) were fixed 
with 4 % paraformaldehyde at 4°C upon collection and shipped to Katare Lab (University of 
Otago-Dunedin). The tissues were washed in 1x phosphate-buffered saline (PBS) twice and 
transferred to a 15 mL centrifuge tube. Tissues were then rehydrated in 30 % sucrose where it 
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was kept until the tissue sunk to the bottom of the tube. Sucrose solution (30 %) is hypertonic 
and will cause the water to flow into the fixed tissue, and this can prevent freezing artefacts and 
also act as a cryoprotectant. Following rehydration, tissues were washed with 1x PBS twice. 
Cryosection was performed based on our previously published report (Munasinghe et al., 2016). 
Firstly, a piece of formalin-fixed heart tissue extracted from each animal in the group was 
dipped in optimum cutting temperature (OCT 6769006, Thermo Scientific) medium. The tissue 
was completely coated in OCT and equilibrated in the cryostat until the block was frozen and 
become solid. The OCT-coated tissue block was then tightly secured onto the chuck. The 
position of the block was adjusted to align the block with the knife blade. The tissue block was 
sectioned until a suitable desired tissue was exposed. Superfrost Plus microscope glass slides 
(LBS4951plus, LabServ) were used to retrieve the tissue sections on the cryostat stage. Two 
slides with three serial transverse cryosections on each slide with a thickness of 7 μm were used 
for the analysis of apoptosis and fibrosis.  The slides were stored at -80°C until used. 
 
2.6.2 Antigen retrieval 
 
Antigen retrieval is the exposure of antigenic sites to ensure the binding of antibodies. This step 
is carried out before any immunofluorescence staining and in the current thesis only for the 
detection of apoptosis (Terminal deoxynucleotidyl transferase dUTP nick end labelling; 
TUNEL assay). Most formalin-fixed tissue requires an antigen retrieval step before 
immunofluorescence staining as methylene bridges formed during formalin during fixation, 
cross-link with proteins and mask the antigen sites (Syrbu & Cohen, 2011).  Antigen retrieval 
step breaks these methylene bridges and exposes antigenic sites, allowing antibodies to bind. 
Heat-induced antigen retrieval was used in the current study. Firstly, sections were 
deparaffinised by immersing the slides in 2 changes of Xylene (214736-4L, Sigma-Aldrich) 5 
min each. Secondly, sections were rehydrated in two changes of 100 % ethanol 3 min each 
followed by 95 % ethanol (3 min), 85 % ethanol (3 min) and finally in MiliQ water for 5 min. 
Sections were then immersed in sodium citrate buffer (10 mM sodium citrate (6132-04-3, 
Sigma-Aldrich), 0.05 % Tween 20, pH 6.0) and incubated at 95 ̊ C for 1 hour. Sections were 
then cooled for 20 min at room temperature before proceeding to apoptosis (TUNEL assay) 




2.7  Quantification of apoptosis 
 
Cardiomyocyte apoptosis was determined using Click-iT Plus Terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) assay, and the Alexa Fluor 594 dye (C10618, 
Invitrogen). This was performed according to the manufacturer’s instruction TUNEL User 




Following the antigen retrieval step as described in section 2.6.2, the 7 µm ventricular tissue 
sections on slides were washed twice using PBS buffer for 5 min each time. Secondly, sections 
were then permeabilised by incubating the sections with 30 μl of Proteinase K solution for 1 
hour and washed away with PBS buffer for 5 min. Next, the sections were fixed in 4 % 
paraformaldehyde for 5 min at 37°C and washed twice with 1x PBS buffer as per manufacturer's 
recommended protocol.  
 
2.7.2 Enzyme reaction 
 
The slides were then incubated with 30 μLof terminal deoxynucleotidyl transferase (TDT) 
reaction buffer and incubated for 10 min at 37°C. After removing the buffer, 30 μL of the TDT 
reaction mixture was added and incubated at 37°C for an hour. Subsequently, the slides were 
washed with deionised water, followed by 3 % BSA and 0.1 % Triton X-100 in PBS for 5 min 
and finally with PBS.  
 
2.7.3 Addition of fluorophore 
 
Click-iT Plus TUNEL reaction cocktail buffer was prepared according to Table 2.5. The 
cocktail buffer (50 μL) was added to each slide. All slides were incubated at 37°C for 30 min 
in a light-protected chamber. Following incubation, the cocktail buffer was removed, washed 





Table 2.5: Click-iT PLUS TUNEL reaction cocktails. 
Reaction components Volume for 50 reactions (μL) 
Click-iT Plus TUNEL Supermix 2250 
10x Click-iT Plus TUNEL Reaction buffer additive 250 
Total volume 2500 
 
2.7.4 Detection of apoptosis 
 
TUNEL-stained slides were further incubated with cardiomyocyte-specific marker antibody 
against cardiac Troponin I Type 3 (NB110-2546B, Novus Biological) overnight at 4°C and 
counterstained with secondary antibody Alexa Fluor® 488 streptavidin (S32354, 
ThermoFisher) for one hour the following day. The nuclei were counterstained with 0.5 μg/mL 
of DAPI (SC3598, Santa Cruz Biotechnology) for 2 min and washed with 1x TBS buffer. 
Finally, the slide was mounted with Fluoromount-G™ Mounting Medium  (00-4958-02, 
ThermoFisher Scientific).   
 
 Table 2.6: Antibody pairing for the detection of apoptosis. 
Detection Primary staining Secondary staining Tertiary staining 
Cardiac apoptosis TUNEL Cardiac Troponin I Type 3 
antibody 
Alexa Fluro® 488 
Streptavidin 
 
2.7.5 Data Analysis 
 
All slides were visualised under a 20x dry objective lens using an Olympus BX51 Fluorescence 
Microscope. There were three sections per slide, and at least seven areas per slide were 
captured. Apoptosis was expressed as a percentage of TUNEL positive cardiomyocytes nuclei 




2.8  Fibrosis 
 
2.8.1 Picro-Sirius red staining  
 
Cardiac fibrosis was assessed using Picro Sirius red staining according to the published protocol 
(Rawal et al., 2017). As mentioned above (Section 2.6.1), one of the slides stored at -80 ̊C was 
used for this assay. Sections were washed with MilliQ water for 3 min, followed by 1x PBS 
wash for 3 min. The sections were then stained in 1 % Picro-Sirius red for one hour at room 
temperature. The slides were then washed twice with acidified water (5 mL of acetic acid in 1 
L of MilliQ water) followed by dehydration in 50 % ethanol, 85 % ethanol, 95 % ethanol 
sequentially for 3 min each and finally in absolute ethanol for 3 min. Finally, the slides were 
cleared with xylene for 30 sec and mounted with DPX (06522, Sigma). 
 
2.8.2 Assessment and quantification of fibrosis 
(data analysis) 
 
A whole ventricular section was imaged using an Olympus AX70 (Model # U-MPH 5H01919) 
at 4x dry objective lens. Cardiac fibrosis was quantified by capturing 3 whole ventricular 
images per sample (3 sections per slide) and expressed as a percentage of the fibrotic area by 
normalising the polarised tissue area to total cardiac tissue area. All data were analysed using 
Image J software (https://imagej.nih.gov/ij/). 
 
2.9  Statistical analysis  
 
GraphPad Prism 8.0.2 software (GraphPad Prism® Version 8.0.2, GraphPad Software, Inc.) was 
used for all statistical analyses. To compare the expression levels of cNNCS (ChAT, VAChT, 
M2AChR, CHT-1, AchE) and pro-survival proteins (pAkt, Akt, Bcl-2) between ND, T1DM 
wildtype, and T1DM ChAT-TG samples at a specific time point one-way ANOVA (non-
parametric) with Kruskal-Wallis test was carried out.  Comparisons were made between the 
study groups at a given time point only for western blot experiments as it was not possible to 
run all the samples in the same blot. 
 
To compare fibrosis and apoptosis data in the left ventricular cardiac tissue between ND, T1DM 
and ChAT TG-T1DM samples, two-way ANOVA (non-parametric) with the use of Geisser-
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Greenhouse correction was carried out. P-value <0.05 was considered to be statistically 
significant. 
 
To compare cardiac function data in the left ventricular tissue between T1DM and ChAT TG-
T1DM samples, two-way ANOVA with the Sidak’s test for multiple comparisons was 
performed by our collaborator Prof Yoshihiko Kakinuma at Nippon Medical School, Japan. P-









3.1 Changes in cNNCS in the ventricles of   
T1DM and ChAT TG T1DM mice 
 
The first aim was to investigate whether T1DM alters the expression of components of the 
cNNCS and if overexpression of the ChAT gene prevents T1DM-induced changes in cNNCS. 
For this purpose, protein expression of the components of cNNCS (ChAT, CHT1, VAChT, 
AChE, and M2AChR) were examined by western blot analysis.  
 
3.1.1 No change in cardiac expression of ChAT 
protein in T1DM mice 
 
In spite of using the recommended antibody used by other publications (Kakinuma et al., 2009; 
Kakinuma et al., 2013), two bands were observed between 70-75 kDa in ND and T1DM mice 
with the pre-stained molecular weight protein standard used. The ratio between the intensity of 
the ChAT positive bands and the total protein (Ponceau S) (25 kDa-100 kDa) were used for 
quantification of the data, as explained in appendix 6. 
 
ChAT protein expression was consistently detected at all time points (Figure 3.1 A-E) between 
ND, T1DM and ChAT TG-T1DM mice. However, ChAT protein expression was not 
statistically different between the ND and T1DM mice at 4-, 8-, 12- and 16-weeks after STZ 
injection (Figure 3.1 A-E). Importantly, compared to ND mice analysis of the overexpression 
of the ChAT gene in the ventricles, resulting in a significant increase of ChAT protein 
expression at all the time points (3.0± 0.2, 3.4± 0.2, 2.1± 0.3 and 2.3± 0.1-fold increase at 4-, 
8-, 12-, and 16-weeks after STZ injection). Furthermore, compared to T1DM mice 
overexpression of the ChAT gene in the ventricles, also resulted in a significant increase of 
ChAT protein expression (4.5± 0.2 and 2.0± 0.1-fold increase at 4- and 16-weeks after STZ 
injection) with an increasing trend at 8-weeks after STZ injection (p<0.07). These results 
confirmed the successful overexpression of the ChAT gene in the ChAT TG animals and 
confirmed that the induction of diabetes by STZ injection did not affect the overexpression of 














Figure 3.1: Increased ChAT protein expression in ChAT TG-T1DM mice. 
Representative western blots of ChAT protein expression in the ND, T1DM, and ChAT 
TG-T1DM mice at A) 4-, B) 8-, C) 12- and D) 16-weeks after STZ injection. E) Bar 
graphs with scatter plots showing the protein expression of ChAT in ND, T1DM, and 
ChAT TG-T1DM mice. The target protein was normalised to the respective total protein 
(Ponceau S).  Data are presented as mean ± SEM. A non-parametric Kruskal-Wallis test 
was performed. *p<0.05, ***p<0.001 vs age-matched ND mice; #p<0.05, ##p<0.01 vs 
age-matched T1DM mice. n=6 in each group, n=5 in 12W ChAT TG-T1DM. 
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3.1.2 Decreased cardiac expression of CHT-1 
protein in T1DM mice 
 
As per the manufacturer’s recommendation, two bands between 70 to 75 kDa were quantified 
as the CHT-1 positive bands. This is due to protein modification which has been reported 
(https://www.uniprot.org/uniprot/Q9GZV3).  
 
CHT-1 protein expression was consistently detected at all time points (Figure 3.2 A-E) in all 
three animal groups (ND, T1DM and ChAT TG-T1DM). However, CHT-1 protein expression 
was not statistically different between the ND, T1DM and ChAT TG-T1DM mice at 4-, 8-, and 
12-weeks after STZ injection (Figure 3.2 A-E). Interestingly, CHT-1 expression in T1DM mice 
at 16-weeks after STZ injection was significantly decreased (0.49±0.1-fold decrease vs ND 
mice, Figure 3.2 D & E). Importantly, at the same time overexpression of the ChAT gene in the 
ventricles resulted in a significant increase in CHT-1 expression (1.2±0.2-fold increase vs 
T1DM mice, figure 3.3 E). As CHT-1 is the rate-limiting step in the ACh synthesis, it suggests 
a decrease in the uptake of choline for ACh synthesis in T1DM, and the decrease in ACh 














Figure 3.2: Decreased CHT-1 protein expression in ChAT TG-T1DM mice. 
Western blots of CHT-1 protein expression in the ND, T1DM, and ChAT TG-T1DM 
mice at A) 4-, B) 8-, C) 12- and D) 16-weeks after STZ injection. E) Bar graphs with 
scatter plots showing the protein expression of ChAT in ND, T1DM, and ChAT TG-
T1DM mice at 4-, 8-, 12- and 16-weeks after STZ injection. The target protein was 
normalised to the respective total protein (Ponceau S). Data are presented as mean ± 
SEM. A non-parametric Kruskal-Wallis test was performed. **p<0.01 vs age-matched 




3.1.3 No change in cardiac expression of VAChT 
protein in T1DM and ChAT TG-T1DM mice 
 
A VAChT-positive band appeared at 70 kDa and was used for quantification. This is in 
agreement with a study by Guzman et al. (Guzman et al., 2011) that validated the antibody in 
striatum-specific VAChT knockout mice. In these mice, no band was observed at 70 kDa.  
In the current study, a band at 70 kDa was observed consistently across ND, T1DM and ChAT 
TG-T1DM mice at all time points. 
 
VAChT protein expression was not statistically different between the ND, T1DM and ChAT 
















Figure 3.3: VAChT protein expression in ND, T1DM and ChAT TG-T1DM mice. 
Western blots of VAChT protein expression in ND, T1DM, and ChAT TG-T1DM mice 
at A) 4-, B) 8-, C) 12- and D) 16-weeks after STZ injection. E) Bar graphs with scatter 
plots showing the protein expression of VAChT in ND, T1DM, and ChAT TG-T1DM 
mice at 4-,8-,12- and 16-weeks after STZ injection. The target protein was normalised 
to the respective total protein (Ponceau S). Data are presented as mean ± SEM. A non-




3.1.4 Decreased cardiac expression of AchE 
protein in ChAT TG-T1DM mice 
 
As per the manufacturer’s predicted molecular weight of 68 kDa, a band near the 60 kDa was 
quantified as the AChE positive band. A band at 68 kDa was consistently observed across all 
ND, T1DM and ChAT TG-T1DM mice at all time points. 
 
AChE protein expression was not statistically different between the ND, T1DM and ChAT TG-
T1DM mice at 4-, 8-, and 12-weeks after STZ injection (Figure 3.4 A-C). However, at 16-
weeks after STZ injection, overexpression of the ChAT gene in the ventricles resulted in a 
significant decrease in AChE expression (0.65±0.04-fold decrease vs T1DM, Figure 3.4 D & 
E) and a decreasing trend at 4-weeks after STZ injection (p<0.09) compared to ND mice. In 
conjunction with the preserved CHT-1 expression, reduced AChE at 16-weeks after STZ 















Figure 3.4: Decreased AChE protein expression in ChAT TG-T1DM mice. 
Western blots of AChE protein expression in ND, T1DM, and ChAT TG-T1DM mice 
at A) 4-, B) 8-, C)12- and D) 16-weeks after STZ injection. E) Bar graphs with scatter 
plots showing the protein expression of AChE in ND, T1DM, and ChAT TG-T1DM 
mice at 4-, 8-, 12- and 16-weeks after STZ injection. The target protein was normalised 
to the respective total protein (Ponceau S). Data are presented as mean ± SEM. A non-
parametric Kruskal-Wallis test was performed. ##p<0.01 vs age-matched T1DM mice. 




3.1.5 Increased cardiac expression of M2AchR 
protein in ChAT TG-T1DM mice 
 
As per the manufacturer’s predicted molecular weight of 52 kDa, a band near the 50 kDa with 
the pre-stained molecular weight protein standard was quantified as the M2AChR positive band. 
A band at 52 kDa was consistently observed across all ND, T1DM and ChAT TG-T1DM mice 
at all time points. 
 
M2AChR protein expression was not statistically different between the ND and T1DM mice at 
4-, 8-, 12-and 16-weeks after STZ injection (Figure 3.5 A-E). However, overexpression of the 
ChAT gene in the ventricles resulted in a significant increase in M2AChR expression (2.2±0.14, 
2.3±0.19 and 1.7±0.1-fold increase vs ND mice at 8-, 12-, and 16-weeks after STZ injection, 
Figure 3.5 D-E). These results suggest that overexpression of the ChAT gene in the ventricles 
increased M2AChR density for ACh binding, thereby activating the ACh mediated M2AChR 














Figure 3.5: Increased M2AChR protein expression in ChAT TG-T1DM mice. 
Western blots of M2AChR protein expression in the ND, T1DM, and ChAT TG-T1DM 
mice at A) 4-, B) 8-, C)12- and D) 16-weeks after STZ injection. E) Bar graphs with 
scatter plots showing the protein expression of M2AChR in ND, T1DM, and ChAT TG-
T1DM mice at 4-, 8-, 12- and 16-weeks after STZ injection. The target protein was 
normalised to the respective total protein (Ponceau S). Data are presented as mean ± 
SEM. A non-parametric Kruskal-Wallis test was performed. *p<0.05, **p<0.01 vs age-




In summary, cNNCS component CHT-1 significantly decreased in T1DM  mice compared to 
ND mice at later stages leading to decreased Ach synthesis. However, compared to T1DM mice, 
the overexpression of the ChAT gene in the ventricles (ChAT TG-T1DM mice) significantly 
increased cNNCS component M2AChR from early stages of T1DM, and significantly decreased 
AchE at later stages collectively leading to increased ACh synthesis. 
 
3.2 Changes in pro-survival pathways in 
T1DM and ChAT TG-T1DM mice 
 
Our second aim was to investigate whether T1DM impairs the pro-survival pathways (Akt 
pathway) and if overexpression of the ChAT gene in the ventricles activates pro-survival 
pathways (Akt pathway) in the T1DM setting preventing fibrosis and apoptosis. For this 
purpose, protein expression of the downstream targets of the Akt pathway such as pAkt, Akt 
and Bcl-2 were examined by western blot analysis (Chaanine & Hajjar, 2011; Hemmings & 
Restuccia, 2012; Maillet et al., 2013).  
 
3.2.1  Decreased cardiac expression of pAkt/Akt 
protein in T1DM mice 
 
As per the manufacturer’s predicted molecular weight of 60 kDa with the pre-stained molecular 
weight, protein standard was quantified as the pAkt and Akt positive band. The membrane was 
first exposed to pAkt and then washed with a stripping buffer (10 % sodium dodecyl sulfate, 
0.5M Tris HCL, 08 % β-mercaptoethanol) to remove the pAkt antibody before exposing to Akt 
antibody. The ratio between the intensity of the total Akt positive bands and the pAkt were used 
for quantification of the data.  
 
Protein expression of pAkt/Akt in T1DM mice resulted in a significant decrease of (0.3±0.02 
0.29±0.09, 0.31±0.04 and 0.25±0.06-fold decrease vs ND mice at 4-,8-,12-, and 16-weeks after 
STZ injection, Figure 3.6 A-E). However, the overexpression of the ChAT gene in the ventricles 
prevented the downregulation of pAkt/Akt expression (1.2±0.58, 1.0±0.29, 1.0±0.12 and 
1.5±0.23-fold increase vs T1DM mice at 4-, 8-, 12-, and 16-weeks after STZ injection, Figure 
3.6 A-E). These results suggest that overexpression of the ChAT gene in the ventricles may 
have activated the Akt pathway. Therefore, to confirm the activation of the Akt pathway, a 















Figure 3.6: pAkt, Akt protein expression in ChAT TG-T1DM mice. 
Western blots of pAkt/Akt protein expression in the ND, T1DM, and ChAT TG-T1DM 
mice at A) 4-, B) 8-, C)12- and D) 16-weeks after STZ injection. E) Bar graphs with 
scatter plots showing the protein expression of pAkt/Akt in ND, T1DM, and ChAT TG-
T1DM mice at 4-, 8-, 12- and 16-weeks after STZ injection. The target pAkt protein 
was normalised to the respective total Akt protein. Total Akt protein was normalised to 
the respective total protein (Ponceau S). Data are presented as mean ± SEM. A non-
parametric Kruskal-Wallis test was performed. *p<0.05, **p<0.01 vs age-matched ND 




3.2.2  Decreased cardiac expression of Bcl-2 
protein in T1DM mice 
 
Bcl-2 is an anti-apoptotic protein that plays a vital role in the cross-talk and coupling of the 
Akt pathway to reduce apoptosis, thereby reducing oxygen demand in the heart (Hussain et 
al., 2012). 
 
As per the manufacturer’s predicted molecular weight of 26 kDa with the pre-stained molecular 
weight, protein standard was quantified as the Bcl-2 positive band. The ratio between the Bcl-
2 positive band and the total protein (Ponceau S) (25 kDa-100 kDa) was used for quantification 
of the data. 
 
Protein expression of BCl-2 in T1DM mice resulted in a significant decrease of  (0.4±0.04 
0.4±0.03, 0.3±0.03 and 0.2±0.03-fold decrease vs ND mice at 4-, 8-, 12-, and 16-weeks after 
STZ injection, Figure 3.7 A-E). In contrast, the overexpression of the ChAT gene in the 
ventricles resulted in a significant increase in Bcl-2 expression (0.9±0.1, 1.0±0.08, 1.3±0.11 
and 1.4±0.18-fold increase vs T1DM mice at 4-, 8-, 12-, and 16-weeks after STZ injection, 
Figure 3.7 A-E). These results suggest that overexpression of the ChAT gene in the ventricles 
















Figure 3.7 Increased Bcl-2 protein expression in ChAT TG-T1DM mice. 
Western blots of Bcl-2 protein expression in ND, T1DM, and ChAT TG-T1DM mice 
at A) 4-, B) 8-, C)12- and D) 16-weeks after STZ injection. E) Bar graphs with scatter 
plots showing the protein expression of Bcl-2 in ND, T1DM, and ChAT TG-T1DM 
mice at 4-, 8-, 12- and 16-weeks after STZ injection. The target protein was normalised 
to the respective total protein (Ponceau S). Data are presented as mean ± SEM. A non-
parametric Kruskal-Wallis test was performed. *p<0.05, **p<0.01 vs age-matched ND 




3.3 Increased apoptosis in T1DM is 
prevented in ChAT TG-T1DM 
 
Cardiomyocyte cell death or apoptosis is the hallmark of T1DM linked CVD, and this has been 
demonstrated in both T1DM human and mice cardiac tissue (Chowdhry et al., 2007). Therefore, 
TUNEL assay was performed to determine apoptosis in T1DM mice and to determine the effect 
of overexpression of the ChAT gene at 4- (early-stage)- and 16- (late-stage) weeks after STZ 
injection. TUNEL assay was limited to two-time points due to time constraints (loss of 
laboratory time due to Covid-19 pandemic) and because the pro-survival cascades already 
showed significant changes at the early stage.  
 
A significant increase in apoptosis (TUNEL positive nuclei) was detected in T1DM mice 
(3.4±0.0001 and 3.1±0.0001-fold increase vs ND mice at 4-, and 16-weeks after STZ injection, 
Figure 3.8 A-G). The overexpression of the ChAT gene in the ventricles resulted in a decreasing 
trend in apoptosis (1.4±0.000008; p<0.07 vs T1DM mice 4-weeks after STZ injection, Figure 
3.8 A-C & G) and a significant decrease of apoptosis (1.3±0.0001-fold decrease vs T1DM mice 
16-weeks after STZ injection, Figure 3.8 D-G).  
 
Cardiomyocytes rarely proliferate; therefore, to compensate for the cardiac cell loss, tissue 







Figure 3.8: Effect of T1DM on apoptosis in T1DM and ChAT TG-T1DM mice at 
4- and 16-weeks following STZ injection. 
Representative TUNEL images of (A) ND, (B) T1DM, (C) ChAT TG-T1DM 4-weeks 
after STZ injection and (D) ND, (E) T1DM, (F) ChAT TG-T1DM 16-weeks after STZ 
injection. Cardiomyocyte marker (Cardiac Troponin: Green), apoptosis (TUNEL: 
Pink), nucleus (DAPI: Blue). (G) Quantitative bar graphs showing the TUNEL positive 
nuclei per total nuclei. Data are presented as mean ± SEM. A non-parametric two-
way ANOVA with the use of Geisser-Greenhouse correction was performed. 
**p<0.01, ***p<0.001 vs age-matched ND mice; #p<0.05 vs age-matched T1DM mice. 
n=6 in all groups. 
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3.4 Increased cardiac fibrosis in T1DM is 
prevented in ChAT TG-T1DM 
 
Tissue scarring due to cell loss in the form of cardiac fibrosis is the accumulation of 
extracellular matrix components leading to disrupted cardiac function in the T1DM heart in 
both mice and human due to impaired activity of pAkt/Akt (Figure 3.6) (Russo & 
Frangogiannis, 2016; Rawal et al., 2017; De Blasio et al., 2020). Picro-Sirius red staining was 
used to determine the cardiac fibrosis. Cardiac fibrosis is expressed as a percentage of the total 
fibrotic area (polarised area) to the total tissue area (red-stained area). Cardiac fibrosis was 
significantly increased in T1DM mice at all time points (7.9±0.002, 8.2±0.001, 9.6±0.02, 
22.8±0.04-fold increase at 4-,8-,12-, and 16-weeks after STZ injection compared to ND, Figure 
3.9-3.13), confirming that the progression of the T1DM- associated cardiac fibrosis leads to 
cardiovascular dysfunction (Russo & Frangogiannis, 2016; De Blasio et al., 2020). The 
overexpression of the ChAT gene in the ventricles resulted in significant prevention of cardiac 
fibrosis (0.97±0.003, 0.71±0.001, 1.66±0.006, 1.62±0.007-fold decrease at 4-, 8-, 12, and 16-
weeks after STZ injection compared to T1DM mice, Figure 3.9-3.13). These observations 
provide evidence that overexpression of the ChAT gene in the ventricles prevents cardiac 





Figure 3.9: Effect of T1DM on fibrosis in T1DM and ChAT TG-T1DM mice at 4-
weeks following STZ injection.  
Representative histology images of Picro-Sirius red staining (A) bright-field image of 
ND, (B) polarised image of ND, (C) bright-field image of T1DM, (D) polarised image 





Figure 3.10: Effect of T1DM on fibrosis in T1DM and ChAT TG-T1DM mice at 
8-weeks following STZ injection. 
Representative histology images of Picro-Sirius red staining (A) bright-field image of 
ND, (B) polarised image of ND, (C) bright-field image of T1DM, (D) polarised image 






Figure 3.11: Effect of T1DM on fibrosis in T1DM and ChAT TG-T1DM mice at 
12-weeks following STZ injection. 
Representative histology images of Picro-Sirius red staining (A) bright-field image of 
ND, (B) polarised image of ND, (C) bright-field image of T1DM, (D) polarised image 
of T1DM, (E) bright-field image of ChAT TG-T1DM, (F) polarised image of ChAT 
TG-T1DM 
 
Figure 3.12: Effect of T1DM on fibrosis in T1DM and ChAT TG-T1DM mice at 
16-weeks following STZ injection. 
Representative histology images of Picro-Sirius red staining (A) bright-field image of 
ND, (B) polarised image of ND, (C) bright-field image of T1DM, (D) polarised image 





Figure 3.13: Quantitative bar graphs showing the fibrotic area in the ventricles.  
Values are expressed as a percentage of the total fibrotic area (polarised tissue area) in 
the total tissue area. Data are presented as mean ± SEM. A non-parametric two-way 
ANOVA with the use of Geisser-Greenhouse correction was performed. 
*p<0.05, **p<0.01 vs age-matched ND mice; #p<0.05, ##p<0.01 vs age-matched T1DM 
mice. n=6 in each group, n=5 in 12W ChAT TG-T1DM. 
 
In summary, downstream protein targets of Akt pathway such as pAkt/Akt and Bcl-2 
significantly decreased in T1DM  mice compared to ND mice, leading to increased cardiac 
apoptosis and fibrosis. However, compared to T1DM mice, the overexpression of the ChAT 
gene in the ventricles (ChAT TG-T1DM mice) significantly prevented cardiac apoptosis and 
fibrosis by upregulating the pAkt/Akt and Bcl-2 protein expression. 
 
3.5 Impaired cardiac function in T1DM is 
prevented by the overexpression of the 
ChAT gene 
 
To determine if the alteration in the cNNCS components and increased apoptosis in T1DM 
heart is associated with impaired cardiac function, the pressure-volume catheter method was 
used to measure the LV function of T1DM and ChAT TG-T1DM mice as described by Oikawa 
et al. (Oikawa et al., 2016). These experiments were performed by our collaborator Prof 
Yoshihiko Kakinuma (Nippon Medical School, Japan) who provided the raw data for analyses 
in the current thesis. Systolic function was assessed, as shown in table 3.1. In regards to systolic 
function, parameters such as end-diastolic pressure (EDP),  end-diastolic volume (EDV), 
ejection fraction (EF), systolic pressure (ESP), and end-systolic volume (ESV) were analysed. 
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Age-matched ND cardiac function raw data were available for ESV, EDV, heart rate (HR) and 
EF from a previous study conducted by Katare et al. at the same time points as the current study 
(Katare et al., 2010). However, age-matched ND cardiac function raw data for EDP and ESP 
were not available from the Katara el al. (Katare et al., 2010) study. Therefore, T1DM mice 
cardiac function data for EDP and ESP were compared to published age-matched ND cardiac 
function data of the same animal model (Bennett et al., 2013; Moore et al., 2014). 
 
EDP was not statistically different between ND, T1DM and ChAT TG-T1DM mice at any time 
point (Figure 3.14 A) (Bennett et al., 2013; Moore et al., 2014). However, compared to ND 
mice (Katare et al., 2010) a significant increase in EDV (47.61±4.35 µL, 45.53±1.21 µL, 
48.78±8.62 µL, Figure 3.14 B)  along with a significant decrease in EF (49.37±4.55 %, 
49.88±2.88 %, 45.17±3.17 % at 4-, 8-, and 16-weeks after STZ injection, Figure 3.14 E) was 
observed in T1DM mice (Katare et al., 2010). Overall this is indicative of systolic dysfunction 
observed in T1DM mice compared to ND (Katare et al., 2010).  
 
ESP in T1DM mice compared to ND mice decreased (Figure 3.14 C) at 16-weeks after STZ 
injection (Bennett et al., 2013; Moore et al., 2014), along with a significant increase of ESV 
(24.88±4.46 µL, 22.81±1.51 µL, 26.72±5.20 µL, Figure 3.14 D) at 4-, 8-, and 16-weeks after 
STZ injection (Katare et al., 2010). HR was not affected at any time point in both ND and 
T1DM mice (Figure 3.14 F). Overall, this is indicative of systolic dysfunction observed in 
T1DM mice compared to ND. Therefore, these results suggest that alteration in cNNCS and its 
downstream targets are associated with an impairment in the cardiac function.  
 
Importantly, the overexpression of the ChAT gene in the ventricles markedly improved the LV 
function in the T1DM heart. EDP was not statistically different in the ChAT TG-T1DM mice 
compared to T1DM mice at any time point (Figure 3.14 A). However, overexpression of the 
ChAT gene in the ventricles significantly decreased EDV (36.32±4.34 µL, 37.49±3.21 µL vs 
T1DM mice at 4- and 8-weeks after STZ injection, Figure 3.14 B), suggesting preserved 
systolic function. Likewise, overexpression of the ChAT gene in the ventricles at 16-weeks 
after STZ injection prevented the development of systolic dysfunction, as revealed by a 
significant increase in ESP (82.60±2.92 mmHg vs T1DM mice, Figure 3.14 C) and a significant 
decrease in ESV (14.13±2.43 µL, 15.23±1.47 µL, 13.13±3.65 µL vs T1DM mice at 4-, 8-, and 
16-weeks after STZ injection, Figure 3.14 D). Importantly, this was associated with a marked 
improvement in the EF (61.12±2.26 %, 59.25±1.54 %, 68.13±6.97 % vs T1DM mice at 4-,8-, 
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and 16-weeks after STZ injection, Figure 3.14 E). The HR of mice was unaltered at all time 
points following the overexpression of the ChAT gene in the ventricles (Figure 3.14 F).  
 
Table 3.1: Left ventricular index measurements for functional analysis. 
Left ventricle index  Definition 
End Diastolic Volume (EDV) amount of blood in the ventricles before contraction 
End Diastolic Pressure (EDP) the pressure exerted in the ventricles before contraction 
End Systolic Volume (ESV) amount of blood in the ventricles at the end of a contraction 
End Systolic Pressure (ESP) the pressure exerted in the ventricles at the end of a 
contraction 
Heart Rate number of contractions per minute 


















Figure 3.14: Overexpression of the ChAT gene improved the LV function of ChAT 
TG-T1DM mice.  
Bar graphs with scatter plots showing the systolic function as indicated by (A) end-
diastolic pressure and (B) end-diastolic volume as well as systolic function as indicated 
by (C) end-systolic pressure (D) end-systolic volume (E) ejection fraction and (F) heart 
rate of the ChAT TG-T1DM in comparison to T1DM. Data are expressed as mean ± 
SEM. Two-way ANOVA with Sidak’s test for multiple comparisons was performed. 
*p<0.05 vs age-matched ND mice #p<0.05; ##p<0.01 vs T1DM mice. n=6 in each 




In summary, the cardiac function analysis indicates that the ChAT TG-T1DM mice prevented 











This study aimed to determine whether T1DM impairs the cNNCS components and whether 
the overexpression of the ChAT gene in the ventricles prevents T1DM-mediated CVD through 
the activation of pro-survival pathways. In agreement with our hypothesis, we show that T1DM 
dysregulates the cNNCS components at later stages of the disease  (Figure 3.2). Interestingly, 
the results showed marked impairment in the pro-survival Akt pathway from the early stages 
of the disease, leading to apoptosis and fibrosis (Figure 3.6-3.13) and consequently leading to 
T1DM associated cardiac dysfunction (Figure 3.14). Interestingly, overexpression of the ChAT 
gene in the ventricles prevented diabetes-induced impairment of the cNNCS components 
(Figure 3.1-3.5), hence preserving the downstream pro-survival signalling cascade (Figure 3.6 
& 3.7), resulting in reduced apoptosis (Figure 3.8) and fibrosis (Figure 3.9-3.13). Eventually, 
this prevented the development of diabetes-induced cardiac dysfunction (Figure 3.14).  
 
These data demonstrate that overexpression of the ChAT gene in the ventricles leads to the 
increased availability of ACh (Figure 4.1), which can be developed as a therapeutic approach 




Figure 4.1: Proposed pathway of the overexpression of the ChAT gene in the 
ventricles preventing T1DM associated cardiac dysfunction. 
Cardiomyocyte 1 represents the cNNCS components with the overexpression of the 
ChAT gene in the ventricles, leading to increased ACh synthesis. ACh acts as an auto-
/paracrine mediator stimulating neighbouring cardiomyocytes enabling ACh-M2AChR 
receptor interactions. As a result, it activates the Akt pathway, as shown in 
cardiomyocyte 2, reducing apoptosis and fibrosis and together, preventing T1DM 
associated cardiac dysfunction. Acetylcholine (ACh), choline acetyltransferase 
(ChAT), vesicular ACh transporter (VAChT), acetylcholinesterase (AChE), choline 
transporter (CHT1), type 2 muscarinic ACh receptor (M2AChR), protein kinase B 
(Akt), mammalian target of rapamycin 1& 2 (mTOR-1&-2), b cell lymphoma 2 (Bcl-
2). Original diagram by Emani Munasinghe  
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4.2 STZ-induced animal model 
 
T1DM mice used in the current study were chemically treated with STZ in order to induce 
T1DM, a well-established model in the Katare laboratory along with others (Katare et al., 2010) 
(Jafari Anarkooli et al., 2008; Bennett et al., 2013; Moore et al., 2014). STZ is a glucose 
analogue that enters β-cells via the glucose transporter-2 (GLUT2), which accumulates 
intracellularly forming an alkylating agent that causes DNA methylation (Goyal et al., 2016). 
Further, STZ also increases glucose autooxidation, oxygen-free radical generation, activates 
protein kinase C (PKC) pathway, induces accumulation of AGEs and cytokine secretion (Goyal 
et al., 2016), all of which damage the β cells, resulting in hyperglycaemia, the hallmark of 
T1DM. Therefore, STZ is considered as a unique compound for modelling T1DM in 
humans/animals with acceptable construct and face validity (Goyal et al., 2016).  
 
Reproducibility of the STZ animal model is affected by factors such as variability in 
preparation, route of administration, the dose, animal strain, age and gender of experimental 
subjects. It is also important to note that STZ contributes to cardiovascular complications, 
independent of its ability to cause T1DM. STZ at a 50–60 mg/kg dose in rats impairs the 
autonomic nervous system by increasing parasympathetic activity (increased ACh) and 
decreasing sympathetic activity (Schaan et al., 2004; Goyal et al., 2016). As a consequence, 
this leads to reduced heart rate, reduced force of myocardial muscle 
contraction, hypovolemia and hypotension (Schaan et al., 2004). Furthermore, STZ also 
possesses anti-tumor and anti-bacterial properties. A recent upsurge in reports on STZ-induced 
symptoms of Alzheimer's disease,  retinal neuron death, renal tumours and bone deformities in 
laboratory animals (Bleasel & Yong, 1982; Goyal et al., 2016). Therefore it is essential to 
identify that STZ could also alter the internal environment independent of its ability to cause 
T1DM.  
 
While there are other models of T1DM such as the non-obese diabetic (NOD) mouse and the 
Biobreeding (BB) rat(Van Belle et al., 2009), scientists continue to rely on STZ induced T1DM 
models due to ease of testing, the possibility of biopsy and autopsy and knowledge about its 
genetic and environmental background (Chatzigeorgiou et al., 2009). As of 31st August 2015, 
PubMed showed 24,436 listings on STZ alone and 22,018 listings on STZ and T1DM. This 
evidence denotes extensive use of STZ for induction of experimental T1DM in animals. STZ-
induced diabetes in mice/rats is a valuable tool for T1DM research which has been used by 
many investigators, thereby making the STZ model the ideal means by which to study human 
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T1DM in animals.  Therefore, in the current study, STZ induced T1DM mice model was used 
as the experimental group. 
 
To minimise undesired effects of STZ described above, in the current study, a dosage of 50 
mg/kg (per body weight) of STZ for five days was given via intraperitoneal injection (the route 
of administration) as in previous studies in the Katare laboratory (Katare et al., 2010; Moore et 
al., 2014).  Moreover, to ensure the validity and reproducibility of the chemically induced 
T1DM, STZ preparation, route of STZ administration, STZ dose, animal strain, age and gender 
of experimental subjects were kept consistent (Schaan et al., 2004; Goyal et al., 2016). 
Therefore, STZ-induced diabetes in mice/rats is a valuable tool for T1DM research which has 
been used by many investigators, thereby making STZ model the ideal means by which to study 
human T1DM in animals (Schaan et al., 2004; Katare et al., 2010; Moore et al., 2014; Goyal 
et al., 2016).   
 
4.3 T1DM induce changes in cNNCS 
components at later stages 
 
In the current study, the cNNCS components did not change from 4- to 12-weeks following 
STZ injection in T1DM mice compared to age-matched ND. The underlying mechanism for no 
change in the expression of cNNCS components in the early stages in the T1DM mouse heart 
is not entirely clear, although the following mechanisms could be postulated.  
 
As observed in the current study, Shamir et al. demonstrated that protein expression changes at 
different time scales within a cell (Shamir et al., 2016). Therefore, it could be that cNNCS 
components take less than 4-weeks or longer than 4-weeks to change in the cardiomyocytes 
(Shamir et al., 2016). Secondly, cNNCS components such as electrogenic cation transporters 
(OCTs), butyrylcholinesterase (BChE: complementary to AChE) might have been affected 
(Chatonnet & Lockridge, 1989)and the current study did not investigate the above as the scope 
of this study was to investigate well-established cNNCS components, which are abundantly 
found in the cardiomyocytes (Kakinuma et al., 2005; Kakinuma et al., 2009; Rocha-Resende 
et al., 2012; Kakinuma et al., 2013; Li et al., 2013; Roy et al., 2013). Thirdly, it is important to 




However, the focus of this study was to investigate the expression levels of the key cNNCS 
components in the T1DM setting as it is an area where no studies have been conducted, to the 
best of our knowledge. Therefore it was important to investigate all five key components of 
cNNCS to understand the expression levels at a molecular level in the T1DM setting, while 
different time points were investigated to identify at which time point these change. Though, 
most cNNCS components did not change significantly in the T1DM setting, similar to the 
current study Mabe et al. (Mabe & Hoover, 2011) demonstrated that expression levels of ChAT, 
VAChT and M2AChR in intrinsic cardiac cholinergic neurons of STZ treated T1DM mice also 
remained intact until 16-weeks after STZ injection. Mabe et al. (Mabe & Hoover, 2011) also 
observed that no significant loss of intrinsic cholinergic projections to the heart occurred over 
this time interval. In fact, intrinsic cholinergic nerve density increased at the sinoatrial node of 
T1DM mice, while ChAT, VAChT and M2AChR receptor density remained comparable to ND 
mice until 16-weeks after STZ injection as in the current study. However, similarly to the 
current study, in vivo studies conducted by Mabe et al. (Mabe & Hoover, 2011) did reveal 
cholinergic dysfunction due to decreased levels of ACh, which was manifested as cardiac 
dysfunction as early as 4-weeks of being under T1DM conditions (Mabe & Hoover, 2011). 
Therefore, these observations also suggest that impaired cardiac cholinergic function in mice 
with STZ-induced diabetes results from indirect pathways of defects at upstream/downstream 
of the cardiac ganglia, which became evident in the current study (Mabe & Hoover, 2011).  
 
A significant decrease in CHT-1 expression was observed at  16-weeks after STZ injection 
(Figure 3.2 D-E). As the CHT-1 is the determinant of the rate-limiting step of the ACh synthesis 
(Okuda, 2016), this could lead to a significant decrease in ACh bioavailability.  To confirm the 
role of CHT-1 in the ACh synthesis, Rocha-Resende et al. (Rocha-Resende et al., 2012) 
demonstrated a decrease in ACh synthesis in mouse cardiomyocytes treated with 
hemicholinium-3, a CHT-1 inhibitor to inactivate cNNCS. To further confirm the role of CHT-
1 in ACh synthesis and thereby, influence the cardiac function, Neumann et al. (Neumann et 
al., 2005) determined whether genetic variation in the CHT-1 leads to a variation in the neuronal 
cholinergic system which regulates the heart rate. Compared with the healthy individuals, 
participants having mutated CHT1 gene were significantly associated with heart rate variability, 
thus demonstrating the crucial role of cholinergic activity in the heart.  
 
To further confirm the importance of CHT-1 and the interactions between CHT-1 with cNNCS 
components, Brandon et al. (Brandon et al., 2004)examined the interaction of ChAT and CHT-
1 activity in the neuronal cholinergic system using ChAT (ChAT +/-) heterozygous mice. These 
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heterozygous mice possess one healthy allele and one mutated allele in the ChAT gene leading 
to decreased production of ACh. In these mice, brain ChAT activity was reduced by 40 –50 % 
relative to the homozygous healthy wild-type (ChAT +/+) mice. However, CHT-1 protein and 
mRNA expression level were 50 –100 % higher in heterozygous mice (ChAT +/-) with the 
faulty gene than in homozygous non-mutated wild-type (ChAT +/+) mice. Increased CHT-1 
activity has compensated for the reduced ChAT activity in ChAT +/- mice, contributing to the 
maintenance of normal cholinergic function as reflected by the normal performance of these 
mice in several behavioural assays. These findings suggest that CHT-1 is vital for ACh 
synthesis and bioavailability to maintain cardiac function. 
 
4.4 T1DM-induced increase in cardiac 
apoptosis and fibrosis 
 
One of the adverse consequences of T1DM is cardiomyocyte apoptotic cell death. The presence 
of ROS, AGEs and inflammatory markers trigger the activation of a pro-apoptotic cascade, 
which can lead to augmented cell death (Chowdhry et al., 2007; Li et al., 2008). The current 
study also demonstrated a marked increase in cardiomyocyte apoptotic cell death in T1DM 
heart compared to ND heart, as evidenced by an increase in TUNEL-positive cells in the T1DM 
mice at 4-, and 16-weeks after STZ injection (Figure 3.8). This is likely due to reduced 
activation of Akt and downregulation of pro-apoptotic Bcl-2 as discussed below. 
 
In agreement with the current study, Chiu et al. (Chiu et al., 2001) observed an increase in 
cardiomyocyte apoptotic cell death in both STZ-induced T1DM and genetically-induced T1DM 
OVE26 mice, as evidenced by an increase in TUNEL positive cells. Furthermore, in STZ-
induced diabetic rats, a significant increase in cardiomyocyte apoptotic cell death was also 
observed as early as 3 and 14 days after induction of T1DM  (Fiordaliso et al., 2000). Finally, 
compared with ND patients, T1DM patients were characterised by an 85-fold increase in 
cardiomyocyte apoptotic cell death (Kuethe et al., 2007).  
Adult cardiomyocytes rarely proliferate and the loss of cardiomyocytes due to apoptosis leads 
to tissue scarring augmenting cardiac fibrosis. Studies in animals also showed that 
hyperglycaemia enhanced cardiomyocyte apoptotic cell death was associated with increased 
collagen I deposition leading to cardiac fibrosis (Piek et al., 2016). As shown in Figures 3.9-
3.13, Picro-Sirius red staining of the myocardium showed excessive cardiac fibrosis in the 
T1DM mice from 4- to 16-weeks after STZ injection, which is consistent with other 
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experimental studies involving T1DM patients and mice (van Heerebeek et al., 2008; Falcao-
Pires et al., 2011; Russo & Frangogiannis, 2016).  
 
In addition, excessive formation of advanced glycation end products (AGEs) in diabetes has 
been shown to accelerate cardiac stiffness and adversely alter the elasticity of collagen by post-
translationally modifying collagen matrix through cross-linking (Kong et al., 2014; Russo & 
Frangogiannis, 2016). Hutchinson et al. (Hutchinson et al., 2013) demonstrated an increase in 
AGEs gene expression in type 2 diabetes mellitus (T2DM) mouse heart and more than 10-fold 
increase in the receptor for AGEs (RAGE) expression in the isolated cardiac fibroblasts. This 
observation was accompanied by enhanced cross-linked collagen deposition and interstitial 
fibrosis. As a result, systolic function was impaired in the T2DM heart, indicating poor 
ventricular compliance and increased cardiac stiffness. Therefore, it is reasonable to suggest 
that there is an increase in AGE cross-linking in the T1DM mice from 4- to 16-weeks after STZ 
injection, thereby stiffening the ventricular chamber and resulting in systolic dysfunction as 
shown by the reduced EF and increased in EDV (Figure 3.14 E). 
 
Finally, as the disease progresses, cardiomyocyte apoptotic cell death along with cardiac 
fibrosis could be the main reason leading to compromised cardiac function, which is evident in 
the current study. The manifestation of systolic dysfunction (identified as increased EDV, 
reduced EDP, EF) and systolic dysfunction (identified as increased ESV, decreased ESP) was 
evident in the current study as early as 4-weeks after STZ injection. These findings were also 
observed by other groups where cardiomyocyte apoptotic cell death along with cardiac fibrosis 
led to cardiac dysfunction (Cai et al., 2002; Chowdhry et al., 2007; Katare et al., 2010; Xie et 
al., 2011). Moreover, the current study demonstrated that these changes occur independently 




4.5 Overexpression of the ChAT gene in 
the ventricles increases ACh synthesis 
and bioavailability  
 
Modulation of cNNCS components in the ChAT TG-T1DM mice was observed at all time 
points compared to both ND and T1DM mice. Collectively, a significant increase in the ChAT 
(Figure 3.1), CHT-1 (figure 3.2), M2AChR (Figure 3.5) and a decrease in AChE  (Figure 3.4) 
expression is likely to boost the ACh synthesise and ACh bioavailability. Recently, several 
studies have investigated and demonstrated the beneficial effects of increasing the ACh 
bioavailability in improving the cardiac function (Kakinuma et al., 2005; Kakinuma et al., 
2009; Kakinuma et al., 2013; Li et al., 2013; Roy et al., 2013).It is also important to identify 
that increased cNNCS leading to increased ACh acts as an auto-/paracrine mediator, to 
stimulate neighbouring cardiomyocytes facilitating the propagation of the cholinergic effects 
in the heart.  
 
The current study could not measure the ACh levels directly; however, Kakinuma et al. 
(Kakinuma et al., 2013) showed that overexpression of the ChAT gene in the ventricles 
increased ACh bioavailability. Li et al. (Li et al., 2013) demonstrated that oral administration 
of an acetylcholinesterase inhibitor (Donepezil) to rats with systolic dysfunction (reduced EDP) 
increased synaptic ACh bioavailability and disproportionately increased cholinergic tone to 
improve the cardiac function. To further investigate the beneficial effects of increased ACh 
bioavailability, cardiac-specific VAChT and ChAT knockout mice were subjected to acute low-
intensity treadmill exercises. VAChT and ChAT knockout mice had reduced heart rate recovery 
compared to the age-matched wildtype (Roy et al., 2013), indicating diminished neuronal 
cholinergic tone as a consequence of the impaired ability of cNNCS to synthesise ACh, thereby 
decreasing ACh bioavailability. 
 
ACh plays a role in cell to cell communication, as ACh acts as an auto-/paracrine mediator. 
Kakinuma et al. (Kakinuma et al., 2005) provided evidence that the ACh released from cNNCS 
preserves gap junctional protein (β-catenin and Cx43) expression, facilitating cell to cell 
communication (Kakinuma et al., 2005). The authors inactivated cNNCS by knocking out the 
ChAT gene in both HEK293 cells and adult mouse atrial HL-1 cardiomyocytes, which lead to 
decreased ACh bioavailability (Kakinuma et al., 2005). The expression of β-catenin in ChAT-
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KO HEK293 cells and Cx43 in HL-1 cardiomyocytes was significantly reduced compared with 
control, thereby affecting cell to cell communication (Kakinuma et al., 2005).  
 
To summarise, as observed in the current study, increasing cNNCS components increases ACh 
bioavailability improving cell-cell communication as demonstrated by Kakinuma et al. 
(Kakinuma et al., 2005), thereby facilitating the cholinergic effect, preventing T1DM 
associated cardiac dysfunction (Figure 3.14). 
 
4.6 Overexpression of the ChAT gene in 
the ventricles activates pro-survival Akt 
pathway preventing cardiac 
dysfunction 
 
In the T1DM mice compared to ND mice, cNNCS components were not changed (Figure 3.1-
3.5) until later stages of T1DM; however, cardiac dysfunction was observed at all time points 
(Figure 3.14). Interestingly, pAkt/Akt and Bcl-2 expression were significantly decreased in 
T1DM mice compared to ND mice.  The explanation for the changes in the downstream targets 
of Akt pathway observed, and the lack of change in the cNNCS components could be due to 
downstream targets of the Akt pathway (pAkt/Akt and Bcl-2) being dysregulated irrespective 
of the cNNCS components in the T1DM setting.  
 
The Akt pathway and its downstream targets (pAkt/Akt and Bcl-2) can be activated by insulin 
directly, which is not part of the cNNCS components. In T1DM, insulin-producing β cells are 
destroyed, resulting in a lack of insulin. In contrast, in healthy individuals, insulin produced by 
β cells binds to insulin receptors (IR) found in tissues regulating glucose metabolism, thereby 
reducing hyperglycaemia, along with activating pAkt/Akt and Bcl-2 (Kim et al., 1999; 
Kitamura et al., 1999). Therefore, in the current study, decreased expression of pAkt/Akt and 
Bcl-2 observed could be due to lack of insulin in T1DM, leading to reduced activation of IR, 
thereby reducing Akt pathway activation (Kim et al., 1999; Kitamura et al., 1999). Furthermore, 
hyperglycaemia-induced generation of ROS and AGEs could indirectly impair the Akt pathway 
resulting in decreased pAkt/Akt, Bcl-2 expression and leading to apoptosis and fibrosis in 
T1DM mice (Chaanine & Hajjar, 2011; Hemmings & Restuccia, 2012). In line with this, both 
Katare et al. (Katare et al., 2010) and  Moore et al. (Moore et al., 2014) showed that the 
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phosphorylation level of Akt was decreased in the STZ-induced T1DM  mouse model. Further, 
they demonstrated the downregulation of pro-survival protein proto-oncogene serine/threonine-
protein kinase (Pim-1) and upregulation of pro-apoptotic Caspase-3 leading to cardiac 
dysfunction in STZ-induced T1DM  mouse model as early as 4-weeks after STZ injection 
(Katare et al., 2010; Moore et al., 2014).  
 
Strikingly, the non-neuronal effects mediated through ACh-M2AChR interaction were possibly 
restored after activation of cNNCS through the overexpression in the ChAT gene in the 
ventricles at all time points. Increase in M2AChR protein expression increases ACh- M2AChR 
interaction in the ChAT TG-T1DM mice compared to T1DM mice, in turn, activating 
M2AChR-mediated downstream signalling such as the Akt pathway (Intachai et al., 2018). As 
stated in chapter 1 and 3, ACh-initiated mAChR signalling leads to the activation of the pro-
survival Akt pathway as mAChR is a G protein-coupled receptor (GPCR) (Kakinuma et al., 
2005; Kakinuma et al., 2013). Although it is still not known which subtype of mAChR is 
responsible for activating this signalling pathway, it is safe to assume that M2AChR may be 
involved in this as this subtype is the most abundant mAChR in the heart(Woo et al., 2005; 
Wang et al., 2007; Kitazawa et al., 2009).  
 
Bcl-2 (a downstream target of Akt pathway) is an anti-apoptotic protein which decreases 
cardiomyocyte apoptotic cell death as observed in the ChAT TG-T1DM mice compared to 
T1DM mice. Due to the decrease in cell loss, tissue scarring will also decrease as a secondary 
effect, thereby reducing the cardiac fibrosis. Consistently, Kakinuma et al. (Kakinuma et al., 
2009; Kakinuma et al., 2013)showed that overexpression of ChAT gene in the ventricles 
resulted in an increase in the phosphorylation level of Akt (threonine 308), HIF1α and GLUT-
4 expression in the ChAT-TG mice, indicating activation of PI3K/Akt/HIF1α/GLUT-4 
signalling cascade mediated by the interaction of ACh-M2AChR in the cardiomyocytes.  
 
The current study also showed an increase in the phosphorylation level of Akt (serine 473; 
Figure 3.6) and decreased level of Bcl-2 expression (Figure 3.7) in the ChAT TG-T1DM  mice 
compared to that of the age-matched ND and T1DM mice. These findings support that the pro-
survival Akt signalling cascade was activated in the ChAT TG-T1DM mice. Subsequently, 
systolic function (indicated by ESP and ESV; Figure 3.14 C & D), as well as contractility 
(indicated by EF; Figure 3.14 E), was significantly enhanced in the ChAT TG-T1DM mice 
compared to T1DM mice. Similarly, several studies showed that activation of  the Akt 
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pathway inhibited diabetes-induced cardiomyocyte apoptosis, fibrosis and prevented cardiac 
dysfunction in diabetic animals (Nishikawa et al., 2006; Xie et al., 2011; He et al., 2013). 
 
In line with the current study, Kakinuma et al. demonstrated activation of the cNNCS exerts a 
beneficial effect by reducing oxygen demand to preserve cellular ATP content during oxidative 
stress observed in the T1DM heart (Kakinuma et al., 2005; Kakinuma et al., 2013). The 
molecular mechanism for these protective effects are mediated via ACh- M2AChR interaction, 
leading to activation of the Akt signalling pathway to increase the availability of hypoxia-
inducible factor 1 (HIF-1) under ND condition (Hirota et al., 2004; Kakinuma et al., 2005; 
Kakinuma et al., 2013). As reviewed by Semenza et al. (Semenza, 2014) HIF-1 forms a 
transcription factor in inducing the transcription of a wide spectrum of hypoxia-responsive 
genes, facilitating the adaption to ischemic stress, including angiogenesis and glycolysis to 
balance oxygen supply and demand (Hirota et al., 2004; Kakinuma et al., 2005; Kakinuma et 
al., 2008; Kakinuma et al., 2013; Semenza, 2014).  
 
Firstly, the HIF-1 transcription factor regulates cell survival via activation of the apoptosis 
inhibitor gene (AI). AI gene is responsible for decreasing oxygen consumption and preventing 
apoptosis (Kakinuma et al., 2008). Secondly, the HIF-1 transcription factor regulates glucose 
uptake through its downstream target GLUT-4. GLUT-4 promotes glucose uptake and 
utilisation, lowering cardiac oxygen consumption and generates sufficient ATP (energy) to 
sustain the contractile function (Kakinuma et al., 2013). Thirdly, the HIF-1 transcription factor 
regulates angiogenesis through its pro-angiogenic downstream target vascular endothelial 
growth factor (VEGF). An increase in VEGF expression promotes angiogenesis and enhances 
oxygen supply to the heart of ChAT-TG mice, therefore reducing its susceptibility to the 
diabetes-induced cardiac dysfunction (Kakinuma et al., 2013).  In line with this, cardiac-
specific overexpression of HIF-1α gene shows acute beneficial effects such as improved 
glycolysis, angiogenesis, and prevention of ischemia- and diabetes-induced cardiac dysfunction 
in the rodents (Kido et al., 2005; Xue et al., 2010; Hölscher et al., 2012). Conversely, loss of 
HIF-1 transcriptional pathway leads to cardiac dysfunction due to a combinatory effect of 
decreased vascularity, myocardial energy production and calcium mishandling in the cardiac-
specific HIF-1 knock out mice (Huang et al., 2004). Interestingly, Kakinuma et al. (Kakinuma 
et al., 2013) showed that overexpression of the ChAT gene in the ventricles in the normal heart 




Finally, the overall findings suggest that activation of cNNCS enhances the systolic function in 
the T1DM heart and the underlying mechanism for this beneficial effect is contributed by 




The cNNCS components either lacked changes in the expression or changes were only 
observed at later stages in the T1DM mice, while differential expressional changes in the 
cNNCS components were observed in the ChAT TG-T1DM mice.  Therefore, the following 
aspects need to be taken into consideration while evaluating the results. 
 
4.7.1 Investigating protein expression changes 
for shorter or longer time intervals 
 
Although the advantage of using mice with different durations of T1DM allowed examining 
the temporal expression changes in the components of cNNCS, the results require careful 
interpretation. As there was an interval of 4-weeks between the mice, it is also logical that 
protein expression would take less than 4-weeks or longer than 4-weeks to change in the 
cardiomyocytes (Shamir et al., 2016) raising the question of whether the temporal changes 
represent the genuine biological changes in the T1DM mice. Thus, future study should consider 
examining the temporal expression changes in a shorter age interval (e.g. difference of 1-week) 
or longer (e.g. difference of 6-weeks), and this would better represent the biological changes in 
cNNCS and allow precise data interpretation. 
 
4.7.2 Cardiac ACh level measurement 
 
Measurement of ACh level should have been performed to support the western blot analysis of 
cNNCS expression in the ND, T1DM and ChAT TG-T1DM mouse heart to confirm the ACh 
bioavailability in the heart. However, measuring ACh requires fresh ventricular tissues, which 
was not possible in this study. This is because all the mouse ventricular tissues were previously 




4.7.3 Assessment of cardiac function 
 
The clinical assessment of diastolic function relies on the ratio between the early (E) and late 
(A)  mitral flow velocity, also known as the E/A ratio (Nagueh et al., 2016).  In addition, the 
clinical assessment of systolic function is assessed by the measurement of EF, cardiac output 
(CO) and stroke volume (SV) (Ponikowski et al., 2016). The limitation of the pressure-volume 
loop method is that the same animal cannot be used for the serial follow up, unlike 
echocardiography, as animals will be culled after measurement. Therefore, it would be crucial 
to perform echocardiography to assess the E/A ratio on these animals in a future study to get a 
wider understanding of both the diastolic and systolic function. 
 
4.7.4 Ageing effect in all three study groups 
 
To effectively compare the expression changes of cNNCS and its downstream targets between 
age-matched ND, T1DM and ChAT TG-T1DM mice, four protein samples isolated from each 
study group of the same age were loaded on the same gel and processed. By doing this, 
comparison of expression changes of the same protein target between different age groups had 
to be omitted as the experimental condition could vary from time to time. However, it is 
undeniable that ageing is one of the factors that could alter the expression changes.  
 
4.7.5 Gender effect in all three study groups 
 
In the current study, only male mice were selected. Therefore, it would be interesting to 
compare the expression changes of cNNCS and its downstream targets in both male and female 
mice as it is undeniable that gender is one of the factors that could alter the expression as 
observed by Oikawa et al. (Oikawa et al., 2017).  
 
4.7.6 Limited sample size 
 
In the present study, we often observed an increasing or decreasing trend in protein expression, 
while these changes were not statistically significant. This could be due to the number of 
samples (i.e. 6 or 5 mice) being not adequate to detect the differences, specifically looking at 
the cNNCS components. For example, to identify the significant changes in VAChT expression 
in the ChAT TG-T1DM mice at 16-weeks after STZ injection (Figure 3.4), power analysis 
revealed that 11 mice per group are required (80 % power) 
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(https://clincalc.com/stats/samplesize.aspx). Thus, future study should consider performing 
power analysis to determine the sample size needed to detect significant expression changes. 
 
4.7.7 Effect of Isoflurane (anaesthetic drug)  
 
On a side note, the measurement of cardiac function was performed under 1- 2 % isoflurane via 
inhalation (Kakinuma et al., 2013). Isoflurane is known to influence cardiac function and 
hemodynamics (Sawey et al., 2012). However, the influence of isoflurane on the cardiac 
function of mice used in this study should be minimal as previous studies showed that isoflurane 
concentration titrated between 0.5 – 2 % did not induce a significant effect on cardiac function 
(Sawey et al., 2012).  
 
4.7.8 High levels of ACh in ChAT TG-T1DM mice  
 
In ChAT TG-T1DM mice, the overexpression of the ChAT gene in the ventricles leads to 
increased ACh levels from birth, and the T1DM condition is chemically induced at later stages. 
However, in the clinical setting, the development of T1DM leads to low levels of ACh at later 
stages, along with reduced Akt, increased apoptosis and fibrosis. Nevertheless, it is important 
to reiterate that the current study is a proof of concept where increased ACh synthesise and 
bioavailability will be beneficial in treating T1DM-induced pathology. In order to translate to 
the clinical use of our findings, ACh can be increased in patients with the use of drugs such as 
cholinesterase inhibitors that are widely used in the clinic. 
 
4.7.9 Positive control 
 
Due to the limited time, the study did not have access to the animal model ChAT TG 
independent of T1DM, which could have served as the positive control. Therefore it is 
important to include this study group in future studies. 
 
4.8 Future Directions 
 
While we have performed a considerable number of experiments to understand the T1DM-
induced changes in the cNNCS components and the beneficial effects of the overexpression of 
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the ChAT gene in the ventricles, there are still several that can be performed inorder to 
understand this relationship further. 
 
It is also worthwhile to explore other components/ proteins that could be involved in the cardiac 
cholinergic system apart from the well-established components such as ChAT, CHT-1, AChE, 
M2AChR and VAChT. Electrogenic cation transporters (OCTs) are involved in ACh release in 
placental cells (Wessler et al., 2001), urothelial cells (Lips et al., 2007), and airway epithelial 
cells (Kummer et al., 2006). However, OCTs are yet to be explored and studied in the 
cardiomyocytes. Similarly, AChE and butyrylcholinesterase (BChE) are reported to be 
complementary to each other (Chatonnet & Lockridge, 1989). Therefore, it would be interesting 
to investigate the presence and function of these components/ proteins in cardiomyocytes, 
specifically as the cNNCS components investigated in the current study did not change at early 
stages. However, this is beyond the scope of this study, and it could be considered for future 
study.  
 
In addition, the present study also only measured the pAkt, Akt and Bcl-2 proteins from the left 
ventricular tissues of ND, T1DM and ChAT TG-T1DM mice as downstream targets of the 
PI3K/Akt pathway. Investigating GLUT4 (transports glucose in the cardiomyocytes), and  
HIF1-α (forms new blood vessels) could have provided further complete insight into the 
prevention of T1DM associated cardiac dysfunction.  
 
Our experiments have relied on overexpressing the ChAT gene in the ventricles as a method to 
understand the beneficial effects in the T1DM setting at a molecular level. Therefore, to confirm 
the observations of the current study, it is also important to understand the impact of the 
reduction of ChAT expression by loss of function by knocking out the ChAT gene in the 
ventricles in the T1DM setting. The experiment could be performed in in-vivo T1DM models 
where deterioration of LV function, increased apoptosis and fibrosis might be observed. The 
outcome from the experiments will complement the findings derived from the present study 
and further strengthen the role of cNNCS in T1DM. 
By overexpressing the ChAT gene in the ventricles, we are potentially increasing the ACh 
availability in the heart, and medication (Kakinuma et al., 2009) can achieve this.  Medication 
such as 'Donepezil' is an AChE (the enzyme that breaks down ACh) inhibitor resulting in 
increased ACh availability and used in treating Alzheimer's disease (Burns et al., 1999). 
Therefore, in a future study, it would be interesting to treat the T1DM mice with Donepezil to 
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assess whether this strategy improves cardiovascular functions in comparison to the non-treated 
T1DM mice. The use of T1DM mice with different age groups could provide valuable insight 
into the treatment. For example, treating the T1DM mice before established cardiac dysfunction 
would demonstrate whether the Donepezil could prevent the manifestation of T1DM associated 
CVD. Treating the T1DM mice after established cardiac function would confirm whether 
Donepezil is effective in improving the effect of T1DM associated CVD. The outcome would 
further position the role of Donepezil as a therapeutic treatment when translating to the clinics.  
 
Finally, this research has begun to show the T1DM-induced changes in the cNNCS component. 
Therefore, it would be interesting to investigate T2DM-induced changes in the cNNCs 
components to compare and contrast between the two types of diabetic models. This would 
allow research into how these two types of diabetes induce changes in cNNCS components and 






This research has shown that T1DM impairs specific components of cNNCS at later stages of 
the disease, potentially leading to reduced ACh synthesis (Table 4.1). Specifically, pro-survival 
signalling Akt pathway is impaired in T1DM, leading to apoptosis and fibrosis at early stages, 
which are independent of cNNCS components (Table 4.1), collectively leading to  T1DM 
associated cardiac dysfunction (Table 4.2). 
 
We have given evidence that the overexpression of the ChAT gene in the ventricles activates 
cNNCS components from early stages leading to the activation of the downstream pro-survival 
signalling pathway (Akt pathway), resulting in decreased apoptosis and fibrosis (Table 4.1). 
We have also shown preliminary evidence that as a consequence of activated cNNCS 
components and its downstream targets prevents T1DM cardiac dysfunction (Table 4.2). 
 
Together this research allows us to begin to understand how T1DM impacts at a molecular level 
of dysregulating specific cNNCS components at later stages leading to cardiac dysfunction. 
This response involves a complex integration of systems, and this is only one mechanism by 
which we are beginning to understand how it affects T1DM associated cardiac dysfunction. 
Our findings begin to unravel an essential mechanism for endogenous expression of the cNNCS 
components and its impact on the cardiac function within the T1DM setting.   
 
The overall findings from this study extended the knowledge of pathology at a molecular level 
in the T1DM setting and the role of cNNCS in the T1DM heart. Results gathered from the 
current study will facilitate the understanding of both T1DM- and T2DM-induced 
dysregulation of the non-neuronal/ neuronal cholinergic system and its functional role in 
pathology at a molecular level. Last but not least, this thesis provides a strong foundation that 




Table 4.1: Summary of protein expression changes in the components of cNNCS and survival 
proteins in the ventricles of T1DM and ChAT TG-T1DM mice.  
 
Red arrows indicate protein expression changes in T1DM compared to ND; Blue arrows indicate protein 
expression change in ChAT TG-T1DM compared to T1DM; Green arrows indicate protein expression 
changes in ChAT TG-T1DM compared to ND; No arrows indicate no change in protein expression. 
 
Table 4.2: Summary of left ventricular functional changes of T1DM and ChAT TG-T1DM mice.  
 
Red arrows indicate left ventricular functional changes in T1DM compared to ND; Blue arrows 
indicate left ventricular functional changes in ChAT TG-T1DM compared to T1DM; No arrows 
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Appendix 1 - BSA standard curve and protein 
quantification  
 
A standard curve with serial dilutions of protein concentrations was constructed using bovine 
serum albumin (BSA, A7906-500G, Sigma Aldrich) as shown in table S1.0. Protein 
concentrations were determined after plotting the absorbance against the protein standards 
(Figure S1.0 & table S1.1). For western blot analysis, ventricular tissue proteins were diluted 
with 6x Laemmli buffer to a final protein concentration of 1 μg/μL (Table S1.2). 
 
Table S1.0: Preparation of BSA standards for Bradford assay 
Tube # BSA volume 
(μL) 






1 20 2 mg/mL stock 0 2,000 
2 30 2 mg/mL stock 10 1,500 
3 20 2 mg/mL stock 20 1,000 
4 20 Tube 2 20 750 
5 20 Tube 3 20 500 
6 20 Tube 5 20 250 
7 20 Tube 6 20 125 
8 - - 20 0 
 
 
Figure S1.0: BSA standard curve 






























Average Average - 
Blank 
µg/mL DFX2 Concentration 
(µg/µL) 
133 WT 2 0.99 0.83 0.91 0.90 1110.8 2221.6 2.2 
337 WT 2 1.09 1.02 1.05 1.05 1322.5 2645.0 2.6 
338 WT 2 1.31 1.36 1.33 1.33 1724.9 3449.7 3.4 
339 WT 2 1.08 1.18 1.13 1.13 1434.5 2869.0 2.9 
340 WT 2 0.83 0.82 0.83 0.83 1001.9 2003.7 2.0 
341 WT 2 0.93 0.98 0.96 0.96 1185.4 2370.7 2.4 
30 TG 2 0.82 0.80 0.81 0.81 978.9 1957.7 2.0 
90 TG 2 0.86 0.97 0.91 0.91 1122.8 2245.6 2.2 
128 TG 2 1.20 1.20 1.20 1.20 1527.8 3055.6 3.1 
135 TG 2 0.57 0.74 0.65 0.65 750.1 1500.3 1.5 
138 TG 2 0.75 0.86 0.80 0.80 963.1 1926.3 1.9 
139 TG 2 1.03 1.08 1.05 1.05 1320.2 2640.4 2.6 
  
















133 WT 2.2 81 30 69 
337 WT 2.6 68 30 82 
338 WT 3.4 52 30 98 
339 WT 2.9 63 30 87 
340 WT 2.0 90 30 60 
341 WT 2.4 76 30 74 
30 TG 2.0 92 30 58 
90 TG 2.2 80 30 70 
128 TG 3.1 59 30 91 
135 TG 1.5 120 30 30 
138 TG 1.9 93 30 57 





Appendix 2 - Confirmation of the quantification 
of the protein 
 
16-weeks old T1DM (T1DM duration is  4-weeks) ventricular tissues were homogenised and 
quantified as described in section 2.5.1 and 2.5.2. Two different protein concentrations of 10 
µg/µL and 20 µg/µL were loaded to validate the quantification of the proteins extracted. Same 
T1DM sample with a protein concentration of 10 µg/µL was loaded repeatedly in the first four 
wells, and the last four wells were loaded with the same T1DM with a concentration of 20 
µg/µL (left to right). Image J analysis confirmed that loading was consistent as total Ponceau 
staining band area between 25 kDa and 100 kDa was similar within the same concentration 
group. Evidently, Ponceau staining band area between 25 kDa and 100 kDa was higher in 
samples with a concentration of 20 µg/µL compared to samples with a concentration of 10 










Figure S2.0: Loading of  10 µg/µL and 20 µg/µL of T1DM sample at 16-weeks of 
age. 
A) Representative western blot for total Ponceau staining band area between 25 kDa 
and 100 kDa in the T1DM sample at 16-weeks of age. B) Raw data quantified by Image 
J analysis software C)  Quantitative bar graphs showing the total protein expression 
between 25 kDa and 100 kDa of T1DM sample with 10 µg/µL and 20 µg/µL at 16-
weeks of age. T1DM; Type-1 Diabetic Mellitus.  
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Appendix 3 - Confirmation of consistent 
loading of samples  
 
16-weeks old ND and T1DM (T1DM duration is  4-weeks) ventricular tissue was homogenised 
and quantified as described in section 2.5.1 and 2.5.2. A protein concentration of 10 µg/µL were 
loaded repeatedly in each well, where the first four wells were of the same ND sample, and the 
last four were of the same T1DM sample (left to right). Image J analysis confirmed that loading 
was consistent as CHT-1/Ponceau and M2AChR/ Ponceau ratio was similar within each animal 












Figure S3.0: Consistent loading of  10ug/ul of ND and T1DM mice at 16-weeks of 
age  
A) Representative western blots for CHT-1, M2AchR in ND and T1DM at 16-weeks of 
age. B) Raw data quantified by Image J analysis software C)  Quantitative bar graphs 
showing the protein expression of CHT-1 in the T1DM and ND at 16-weeks of age. D) 
Quantitative bar graphs showing the protein expression of M2AchR in the T1DM and 
ND at 16-weeks of age ND; Non-Diabetic, T1DM; Type-1 Diabetic Mellitus.  
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Appendix 4 - Confirmation of uniform transfer 
across the PVDF membrane 
 
16-weeks old T1DM (T1DM duration is  4-weeks) and ND ventricular tissue were homogenised 
and quantified as described in section 2.5.1 and 2.5.2. A protein concentration of 10 µg/µL were 
loaded repeatedly in each well, where the first four wells were of the same T1DM sample, and 
the last four were of the same ND sample (Figure S4.0). Sample loading was in the opposite 
order, as shown in figure S3.0 A. Image J analysis confirmed that loading was consistent as 
CHT-1/Ponceau and M2AChR/ Ponceau ratio was similar within each animal group (Figure 
S4.0) and was similar to the expression level of figure S3.0 B & C, therefore, confirming the 













Figure S4.0: Consistent loading of  10 µg/µL of T1DM and ND mice at 16-weeks 
of age. 
A) Representative western blots for CHT-1, M2AchR in T1DM and ND at 16-weeks of 
age. B) Raw data quantified by Image J analysis software C) Quantitative bar graphs 
showing the protein expression of CHT-1 in the T1DM and ND at 16-weeks of age. D) 
Quantitative bar graphs showing the protein expression of M2AchR in the T1DM and 
ND at 16-weeks of age ND; Non-Diabetic, T1DM; Type-1 Diabetic Mellitus. 
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Appendix 5 - Confirmation of sample 
variability within the same animal group  
 
To investigate the variability of mouse ventricular tissue even within the same animal group, 
four different 16-weeks old T1DM and ChAT TG-T1DM (T1DM duration is  4-weeks) samples 
with a protein concentration of 10 µg/µL were loaded.  Sampled were loaded as shown in figure 
S5.0 A (left to right).  Image J analysis of total Ponceau staining band area between 25 kDa and 
100 kDa confirmed that different samples within the same animal group had different total 
protein expression levels in the Ponceau staining. The quantification of proteins and loading of 
samples was validated in appendix 1- 3. Therefore, the observed variability could be due to the 










Figure S5.0: Variability of T1DM and ChAT TG-T1DM samples within 
the same animal group at 16-weeks of age.  
A) Representative western blot for total Ponceau staining band area between 
25 kDa and 100 kDa in T1DM and ChAT TG-T1DM (n=4 each; protein 
concentration for each sample was 10ug/ul) samples at 16-weeks of age. B) 
Raw data quantified by Image J analysis software C)  Quantitative bar graphs 
showing the total protein expression between 25 kDa and 100 kDa of T1DM 
and ChAT TG-T1DM (n=4 each; protein concentration for each sample was 
10ug/ul) samples. T1DM; Type-1 Diabetic Mellitus ChAT TG-T1DM: 
cardiomyocyte-specific overexpression of ChAT gene with T1DM.   
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Appendix 6 - Area of the ChAT positive bands  
 
In spite of using the recommended antibody used by other publications (Kakinuma et al., 2009) 
(Kakinuma et al., 2013), two bands were observed between 70-75 kDa in ND and T1DM mice 
with the pre-stained molecular weight protein standard used. Post-translational modifications 
that the ChAT protein undergoes lead to the occurrence of these two bands (Oda, 1999). 
However, the ChAT TG heart showed just one bright band, which could possibly be due to the 
high intensity of the bands appearing as merged bands. Therefore, as per the manufacturer’s 
recommendation, the bands between 70- 75 kDa across all the animals and time points were 
quantified as the ChAT positive bands (Figure S6.0).  
 
As a consequence of the ChAT TG-T1DM high band intensity, the expression of ChAT in ND 
and T1DM were masked. Therefore, when visualising the blot in the Syngene PXi imaging 
system, ChAT TG-T1DM samples were covered to visualise the ND and T1DM together. As 
ND and T1DM were visualised separately from ChAT TG-T1DM, it appears as if they were on 
two separate blots (Figure 3.1 A-D); however, all the samples were run on the same blot.  
 
 
Figure S6.0: Area of ChAT positive bands used for quantification. 
The yellow box represents the area used for quantification. 
 
 
 
 
